<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>MDT Report</title>
  <style>
    :root {
      --border: #e5e7eb;
      --muted: #6b7280;
      --bg: #ffffff;
      --card: #ffffff;
      --soft: #f7f7f8;
      --accent: #2563eb;
    }
    body { font-family: -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif; margin: 24px; background: var(--bg); }
    h1 { font-size: 20px; margin: 0 0 12px 0; }
    h2 { font-size: 16px; margin: 0 0 10px 0; }
    h3 { font-size: 14px; margin: 10px 0 6px 0; }
    .meta { color: var(--muted); font-size: 13px; margin-bottom: 14px; }
    .cols { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }
    .card { border: 1px solid var(--border); border-radius: 12px; padding: 12px 14px; background: var(--card); }
    details { border: 1px solid var(--border); border-radius: 12px; padding: 10px 12px; background: var(--card); }
    summary { cursor: pointer; font-weight: 600; }
    pre { white-space: pre-wrap; word-wrap: break-word; background: var(--soft); padding: 12px; border-radius: 10px; overflow-x: auto; }
    .mono { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace; }
    .mt { margin-top: 12px; }
    .hint { color: var(--muted); font-size: 12px; margin-top: 6px; }
    .warn { color: #b45309; font-weight: 600; }
    table.grid { width: 100%; border-collapse: collapse; font-size: 13px; }
    table.grid th, table.grid td { border: 1px solid var(--border); padding: 8px; vertical-align: top; }
    table.grid th { background: #f3f4f6; text-align: left; }
    /* References section styling */
    .refs-section { border: 1px solid var(--border); border-radius: 12px; padding: 16px; background: var(--card); }
    .refs-title { font-size: 16px; font-weight: 700; color: #1f2937; margin: 0 0 16px 0; padding-bottom: 8px; border-bottom: 2px solid var(--accent); }
    .ref-category { margin-bottom: 16px; }
    .ref-cat-header { font-size: 14px; font-weight: 600; color: #374151; margin-bottom: 10px; padding: 6px 10px; background: linear-gradient(135deg, #f3f4f6 0%, #e5e7eb 100%); border-radius: 6px; }
    .ref-entry { margin-bottom: 10px; padding: 10px 12px; background: #fafafa; border-radius: 8px; border-left: 3px solid var(--accent); }
    .ref-tag { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, monospace; font-size: 12px; font-weight: 600; color: var(--accent); margin-bottom: 6px; word-break: break-all; }
    .ref-details { font-size: 13px; color: #4b5563; line-height: 1.6; }
    .ref-detail-line { margin-bottom: 2px; }
    /* Category-specific colors */
    .ref-guidelines .ref-entry { border-left-color: #059669; }
    .ref-guidelines .ref-tag { color: #059669; }
    .ref-literature .ref-entry { border-left-color: #7c3aed; }
    .ref-literature .ref-tag { color: #7c3aed; }
    .ref-clinical-trials .ref-entry { border-left-color: #dc2626; }
    .ref-clinical-trials .ref-tag { color: #dc2626; }
    .ref-clinical-reports .ref-entry { border-left-color: #d97706; }
    .ref-clinical-reports .ref-tag { color: #d97706; }
    /* Mermaid chart styling */
    .mermaid-container { border-color: #10b981; }
    .mermaid-container > summary { color: #059669; }
    .mermaid-chart { padding: 16px; background: linear-gradient(135deg, #f0fdf4 0%, #ecfdf5 100%); border-radius: 10px; margin-top: 10px; overflow-x: auto; }
    .mermaid-chart svg { max-width: 100%; height: auto; }
    /* Dark mode support */
    @media (prefers-color-scheme: dark) {
      :root {
        --border: #374151;
        --muted: #9ca3af;
        --bg: #111827;
        --card: #1f2937;
        --soft: #374151;
        --accent: #60a5fa;
      }
      body { color: #f3f4f6; }
      h1, h2, h3 { color: #f9fafb; }
      table.grid th { background: #374151; color: #f3f4f6; }
      .refs-title { color: #f9fafb; }
      .ref-cat-header { background: linear-gradient(135deg, #374151 0%, #4b5563 100%); color: #f3f4f6; }
      .ref-entry { background: #374151; }
      .ref-details { color: #d1d5db; }
      .mermaid-chart { background: linear-gradient(135deg, #1f2937 0%, #374151 100%); }
      .stats-card { background: linear-gradient(135deg, #1e3a5f 0%, #1e293b 100%) !important; border-color: #0ea5e9 !important; }
      .stats-card h2 { color: #7dd3fc !important; }
    }
    /* Print button */
    .print-btn {
      position: fixed; top: 20px; right: 20px; z-index: 1000;
      padding: 10px 18px; cursor: pointer;
      background: linear-gradient(135deg, #2563eb 0%, #1d4ed8 100%);
      color: white; border: none; border-radius: 8px;
      font-size: 14px; font-weight: 600;
      box-shadow: 0 2px 8px rgba(37, 99, 235, 0.3);
      transition: all 0.2s ease;
    }
    .print-btn:hover { background: linear-gradient(135deg, #1d4ed8 0%, #1e40af 100%); transform: translateY(-1px); box-shadow: 0 4px 12px rgba(37, 99, 235, 0.4); }
    .print-btn:active { transform: translateY(0); }
    /* Print-friendly styles */
    @media print {
      body { margin: 0; background: white; }
      .card, details { border: 1px solid #ccc; page-break-inside: avoid; }
      details[open] > summary ~ * { display: block; }
      .mermaid-chart { page-break-inside: avoid; }
      .stats-card { background: #f0f9ff !important; -webkit-print-color-adjust: exact; print-color-adjust: exact; }
      .no-print { display: none !important; }
    }
    /* Responsive layout */
    @media (max-width: 768px) {
      body { margin: 12px; }
      .cols { grid-template-columns: 1fr; }
      table.grid { font-size: 11px; }
      table.grid th, table.grid td { padding: 4px; }
    }
  </style>
</head>
<body>
  <button onclick="window.print()" class="print-btn no-print">ğŸ–¨ï¸ Print Report</button>
  <h1>OMGs / MDT Report</h1>
  <div class='card stats-card' style='background: linear-gradient(135deg, #f0f9ff 0%, #e0f2fe 100%); border: 2px solid #0ea5e9; margin-bottom: 16px;'>
<h2 style='margin-top: 0; color: #0369a1;'>ğŸ“Š Pipeline Execution Statistics</h2>
<div style='margin-bottom: 12px;'>
<strong>ğŸ¯ Mode:</strong> <code style='background: #e0f2fe; padding: 2px 8px; border-radius: 4px; font-weight: 600;'>omgs</code>
</div>
<div style='margin-bottom: 12px;'>
<strong>â±ï¸ Total Execution Time:</strong> 128.4 seconds (2åˆ†8ç§’)
</div>
<div style='margin-bottom: 12px;'>
<strong>ğŸ”¢ Total Tokens:</strong>
<ul style='margin: 6px 0 0 20px; padding: 0;'>
<li>Input: 122,940</li>
<li>Output: 3,380</li>
<li>Total: 126,320</li>
</ul>
</div>
<div style='margin-bottom: 8px;'>
<strong>ğŸ¤– Models Used:</strong>
<ul style='margin: 6px 0 0 20px; padding: 0;'>
<li style='margin-bottom: 6px;'>
<strong>anthropic/claude-opus-4.5 (Openrouter)</strong>: 
23 calls, 
126,320 tokens 
(122,940 in / 3,380 out)
</li>
</ul>
</div>
</div>
  <div class="meta">
    <div><b>Timestamp</b>: 2026-01-22_18-37-58</div>
  </div>

  <div class="cols mt">
    <div class="card">
      <h2>Final MDT Output</h2>
      <pre># Final Assessment:
High-grade serous ovarian carcinoma, HRD-positive/BRCA1/2-negative [@OH2201222 | Genomics], currently in clinical remission on first-line niraparib maintenance. Labs demonstrate recovered hematologic parameters (PLT 145Ã—10â¹/L) and normal CA125 (6.45 U/ml) [@20230109|5600622 | LAB] [@20230109|9701878 | LAB]. Pelvic MRI shows no evidence of recurrence [@2022-10-25|MR | MR]; patient tolerating maintenance well with ECOG 1.

# Core Treatment Strategy:
- Continue niraparib maintenance therapy per HRD-positive status and ESMO guidelines [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]
- Schedule pelvic MRI and CA125 surveillance every 3-4 months per standard maintenance follow-up protocols
- CT chest follow-up in 3-6 months for stable right upper lung AV fistula and 4mm nodule [@2022-09-27|CT | CT]
- Complete formal FIGO staging documentation and IHC panel for comprehensive pathologic records

# Change Triggers:
- If CA125 rises &gt;2Ã— ULN or imaging shows new lesions, reassess with PET-CT and consider platinum rechallenge
- If severe thrombocytopenia recurs (PLT &lt;50), hold niraparib and dose-reduce per toxicity management [@pubmed | 40687421]</pre>
<div class='refs-section mt'>
<h3 class='refs-title'>References</h3>
<div class='ref-category ref-guidelines'>
<div class='ref-cat-header'>ğŸ“‹ Guidelines</div>
<div class='ref-entry'>
<div class='ref-tag'>[@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Document: esmo_cpg_epithelialovarian_2023__v00000000, Page 8</div>
<div class='ref-detail-line'>Content: MCBS v1.1 score: 4; ESMO Scale for Clinical Actionabil-</div>
<div class='ref-detail-line'>ity...</div>
</div>
</div>
</div>
<div class='ref-category ref-literature'>
<div class='ref-cat-header'>ğŸ“š Literature</div>
<div class='ref-entry'>
<div class='ref-tag'>[@pubmed | 40687421]</div>
<div class='ref-details'>
<div class='ref-detail-line'>PMID: 40687421 | Front Oncol | 2025-01-01</div>
<div class='ref-detail-line'>Title: Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review.</div>
<div class='ref-detail-line'>DOI: 10.3389/fonc.2025.1542646</div>
</div>
</div>
</div>
<div class='ref-category ref-clinical-trials'>
<div class='ref-cat-header'>ğŸ”¬ Clinical Trials</div>
</div>
<div class='ref-category ref-clinical-reports'>
<div class='ref-cat-header'>ğŸ“„ Clinical Reports</div>
<div class='ref-entry'>
<div class='ref-tag'>[@OH2201222 | Genomics]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Genomics ID: OH2201222 | Date: 2022-01-24</div>
<div class='ref-detail-line'>Content: HRD é˜³æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@20230109|5600622 | LAB]</div>
<div class='ref-details'>
<div class='ref-detail-line'>LAB ID: 20230109|5600622 | Date: 2023-01-09</div>
<div class='ref-detail-line'>Content: ä¸­æ€§ç²’ç»†èƒ% 62.0 % (GRAN) PLTåˆ†å¸ƒå®½åº¦ 10 % (PDW) å—œç¢±æ€§ç»†èƒæ•° 0.06 *10^9/L...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@20230109|9701878 | LAB]</div>
<div class='ref-details'>
<div class='ref-detail-line'>LAB ID: 20230109|9701878 | Date: 2023-01-09</div>
<div class='ref-detail-line'>Content: ç³–é“¾æŠ—åŸ125 6.45 U/ml (CA125) äººé™„ç¾è›‹ç™½4 78.30 pmol/L (HE4)...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@2022-10-25|MR | MR]</div>
<div class='ref-details'>
<div class='ref-detail-line'>MR ID: 2022-10-25|MR | Date: 2022-10-25</div>
<div class='ref-detail-line'>Content: å¯¹æ¯”2021-8-17ï¼šåµå·¢ç™Œæœ¯åï¼Œé˜´é“æ®‹ç«¯æœªè§æ˜æ˜¾å¢åšï¼Œç›†è…”æœªè§æ˜æ˜¾å¼‚å¸¸ä¿¡å·è‚¿å—ï¼Œç›†ç»„åŠè…¹è‚¡æ²Ÿæ·‹å·´ç»“æœªè§æ˜æ˜¾è‚¿å¤§ï¼Œç›†è…”...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@2022-09-27|CT | CT]</div>
<div class='ref-details'>
<div class='ref-detail-line'>CT ID: 2022-09-27|CT | Date: 2022-09-27</div>
<div class='ref-detail-line'>Content: å¯¹æ¯”å‰ç‰‡2021-09-01ï¼šå³ä¸Šè‚ºåŠ¨è„‰åˆ†æ”¯è¿œç«¯å¢ç²—ä¸”ä¸å³ä¸Šè‚ºé™è„‰åˆ†æ”¯ç›¸é€šï¼Œå³ä¸Šè‚ºé™è„‰åˆ†æ”¯å¢ç²—ï¼ŒåŒå‰ã€‚å³è‚ºå°–æ®µè§å°ç»“èŠ‚åŒ...</div>
</div>
</div>
</div>
</div>
    </div>
    <div class="card">
      <h2>Question (raw)</h2>
      <div class="hint">Original user question for observability (passed from main via args.question_raw).</div>
      <pre>åµå·¢ç™Œï¼šæµè°ƒå¦è®¤ä¸­é«˜é£é™©åœ°åŒºæ—…å±…å²ï¼Œå¦è®¤ä½“æ¸©å¼‚å¸¸ç­‰æ–°å† è‚ºç‚ç—‡çŠ¶ã€‚2021.08.26åœ¨å…¨éº»ä¸‹è¡Œæ‰©å¤§æ€§å…¨å­å®«åˆ‡é™¤æœ¯+åŒé™„ä»¶åˆ‡é™¤æœ¯+ç›†è…”è‚¿å—åˆ‡é™¤æœ¯+ç›´è‚ ä¹™çŠ¶ç»“è‚ éƒ¨åˆ†åˆ‡é™¤æœ¯+ä¹™çŠ¶ç»“è‚ é€ å£æœ¯+å¤§ç½‘è†œåˆ‡é™¤æœ¯+ç›†è…”æ·‹å·´ç»“æ¸…æ‰«æœ¯+é˜‘å°¾åˆ‡é™¤æœ¯+è…¹ä¸»åŠ¨è„‰æ—æ·‹å·´ç»“æ¸…æ‰«æœ¯ã€‚æœ¯åç—…ç†ï¼šæ ‡æœ¬ç±»å‹:æ‰©å¤§å­å®«+åŒé™„ä»¶+å·¨å¤§ç›†å—+éƒ¨åˆ†ç›´ä¹™ç»“è‚ +ç›†è…¹è…”å¤šç—…ç¶è‚¿ç˜¤å¤§å°:å·¦ä¾§ï¼š3.5Ã—2Ã—1.5cmï¼›å³ä¾§ï¼š6Ã—5.5Ã—4.5cmè‚¿ç˜¤ä¾§åˆ«:åŒä¾§ç—…ç†ç±»å‹:è…ºç™Œï¼Œç»“åˆå…ç–«ç»„åŒ–ç»“æœï¼ˆI2021-07819ï¼‰ï¼Œç¬¦åˆé«˜çº§åˆ«æµ†æ¶²æ€§ç™Œã€‚å…¶ä»–éƒ¨ä½æƒ…å†µ:å·¦è¾“åµç®¡:è§ç™Œç´¯åŠå³è¾“åµç®¡:è§ç™Œç´¯åŠå­å®«å†…è†œ:èç¼©æ”¹å˜å®«é¢ˆ:æ…¢æ€§ç‚å­å®«è‚Œå±‚:è§ç™Œç´¯åŠï¼›è‚Œå£é—´å¹³æ»‘è‚Œç˜¤ï¼ˆå¤šæšï¼Œç›´å¾„0.5-2cmï¼‰ç›†è…¹è…”å¤šéƒ¨ä½ç—…ç¶:ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ ï¼‰è§ç™Œç´¯åŠï¼Œè‡ªæµ†è†œå±‚æµ¸æ¶¦è‡³æµ…è‚Œå±‚ï¼Œè‚ ç®¡ä¸¤åˆ‡ç¼˜æœªè§ç™Œç´¯åŠã€‚ï¼ˆå¤§ç½‘è†œã€å¤§ç½‘è†œåŠç›†è…”è‚¿å—ã€å·¦ä¾§ç»“è‚ æ—æ²Ÿè…¹è†œã€å°è‚ ç³»è†œè‚¿ç˜¤ã€ä¹™çŠ¶ç»“è‚ ç³»è†œè‚¿ç˜¤ï¼‰è§ç™Œç´¯åŠ.ï¼ˆé˜‘å°¾åŠå‘¨å›´è‚¿å—ï¼‰ æµ†è†œå±‚è§ç™Œç´¯åŠã€‚å…¶ä»–:é€æ£€æ·‹å·´ç»“ï¼ˆ6/24ï¼‰è§ç™Œè½¬ç§»ï¼Œå…¶ä¸­ï¼šå·¦ç›†è…”æ·‹å·´ç»“ï¼ˆ1/4ï¼‰ï¼›å³ç›†è…”æ·‹å·´ç»“ï¼ˆ3/8ï¼‰ï¼›è…¹ä¸»è‚ ç³»è†œä¸‹æ–¹æ·‹å·´ç»“ï¼ˆ1/4ï¼‰ï¼› è‚ ç³»è†œä¸‹åŠ¨è„‰ä¸Šæ–¹æ·‹å·´ç»“ï¼ˆ1/2ï¼‰ï¼›è…¹ä¸»åŠ¨è„‰æ—æ·‹å·´ç»“ï¼ˆ0/6ï¼‰ .
2021.09.06ã€09.07äºˆé¡ºé“‚50mgè…¹è…”åŒ–ç–—ã€2021.10.18èµ·è¡ŒTPåŒ–ç–—6ç¨‹ï¼Œæœ«æ¬¡åŒ–ç–—2022.3.22æˆ‘é™¢åŸºå› æ£€æµ‹ç»“æœï¼šHRD(+)æœç”¨å°¼æ‹‰å¸•åˆ©1å‘¨ï¼Œè¯‰ååº”å¤§ï¼Œè‡ª2022.4.26å¼€å§‹åœè¯ã€‚2022.4.18è¡€å¸¸è§„ï¼šPLT:33ä»Šæ—¥è¡€å¸¸è§„ï¼šPLT:342022.5.23èµ·æ¢å¤å°¼æ‹‰å¸•åˆ©1#qdã€‚
ç›®å‰ååº”å¯ã€‚2022.6.24è‡³ä¸­å±±åŒ»é™¢è¡Œè…¹å£ç–ä¿®è¡¥æœ¯ã€‚å› æ‰‹æœ¯å°¼æ‹‰å¸•åˆ©åœè¯3å‘¨ã€‚ç›®å‰ç»§ç»­å£æœå°¼æ‹‰å¸•åˆ©ä¸­ã€‚è¯‰æœ€è¿‘è…¹ç—›å‡ æ¬¡ï¼Œè…¹èƒ€æ˜æ˜¾ã€‚CTï¼ˆ2022.09.27ï¼‰ï¼šå³ä¸Šè‚ºåŠ¨é™è„‰ç˜˜å¯èƒ½åŒå‰ï¼Œè¯·ç»“åˆä¸´åºŠåŠä¸“é¡¹æ£€æŸ¥ã€‚å³ä¸Šè‚ºå°–æ®µå°ç»“èŠ‚åŒå‰ï¼Œå·¦ä¸Šè‚ºæ•£åœ¨å°å¾®å°ç»“èŠ‚ï¼Œéšè®¿ã€‚ä¸¤ä¾§èƒ¸è…”å†…å°‘é‡ç§¯æ¶²è¾ƒå‰å¸æ”¶ï¼›åŒè‚ºæ•£åœ¨æ…¢æ€§ç‚ç—‡åŠçº¤ç»´ï¼Œè‚ºå¶ä¸å¼ è¾ƒå‰å¥½è½¬ã€‚å³ä¾§å¿ƒè†ˆè§’å¤„ç»“èŠ‚è¾ƒå‰ä¸æ˜æ˜¾ã€‚ç”²çŠ¶è…ºåŠè…¹éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚
CTï¼ˆ2022.10.08ï¼‰ï¼šè‚å³å¶VIIæ®µè¡€ç®¡ç˜¤åŒå‰ã€‚å·¦è‚¾å›Šè‚¿åŒå‰ã€‚è…°æ¤å±€éƒ¨éª¨è´¨ä¸å‡åŒ€è‡´å¯†åŒå‰ï¼Œéšè®¿ã€‚èƒ¸éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚
MRï¼ˆ2022.10.25ï¼‰ï¼šåµå·¢ç™Œæœ¯åï¼Œç›®å‰ç›†è…”æœªè§å¼‚å¸¸è½¯ç»„ç»‡å½±ï¼Œè¯·éšè®¿ã€‚æœ€è¿‘å¤æŸ¥æŠ¥å‘Šå¥½ã€‚2022.12.30ä¸­å±±åŒ»é™¢ï¼šåˆ‡å£ç–ï¼Œè‚å³å¶ä½å¯†åº¦ç¶ã€‚è¡€å¸¸è§„ã€è‚è‚¾åŠŸèƒ½ä¸€èˆ¬å¯; ECOG=1</pre>

      <details class="mt">
        <summary>Case (Structured JSON)</summary>
        <pre>{&quot;CASE_CORE&quot;:{&quot;ADJUVANT_TREATMENT&quot;:{&quot;cycles_or_courses&quot;:&quot;6&quot;,&quot;given&quot;:&quot;Yes&quot;,&quot;regimens&quot;:[&quot;TP&quot;]},&quot;BIOMARKERS&quot;:{&quot;AFP&quot;:&quot;Unknown&quot;,&quot;CA125&quot;:&quot;Unknown&quot;,&quot;HER2&quot;:&quot;Unknown&quot;,&quot;MSI&quot;:&quot;Unknown&quot;,&quot;PDL1_CPS&quot;:&quot;Unknown&quot;,&quot;TMB&quot;:&quot;Unknown&quot;},&quot;BRCA1&quot;:&quot;Unknown&quot;,&quot;BRCA2&quot;:&quot;Unknown&quot;,&quot;CURRENT_STATUS&quot;:&quot;On maintenance niraparib; ECOG 1; recent imaging without pelvic recurrence.&quot;,&quot;DIAGNOSIS&quot;:{&quot;components&quot;:[&quot;Adenocarcinoma&quot;,&quot;High-grade serous carcinoma&quot;],&quot;histology&quot;:&quot;High-grade serous carcinoma&quot;,&quot;laterality&quot;:&quot;Bilateral&quot;,&quot;primary&quot;:&quot;Ovarian cancer&quot;,&quot;site&quot;:&quot;Ovary&quot;},&quot;ECOG&quot;:&quot;1&quot;,&quot;GENOMICS&quot;:{&quot;HRD_STATUS&quot;:{&quot;method&quot;:&quot;Unknown&quot;,&quot;result&quot;:&quot;Positive&quot;,&quot;score&quot;:&quot;Unknown&quot;},&quot;alterations&quot;:[],&quot;testing_date&quot;:&quot;Unknown&quot;,&quot;testing_performed&quot;:&quot;Yes&quot;,&quot;testing_platform&quot;:&quot;Unknown&quot;},&quot;HRD&quot;:&quot;Positive&quot;,&quot;INITIAL_TREATMENT&quot;:&quot;Yes&quot;,&quot;LINE_OF_THERAPY&quot;:[{&quot;concurrent_bevacizumab&quot;:&quot;No&quot;,&quot;cycles_completed&quot;:&quot;1&quot;,&quot;cycles_planned&quot;:&quot;Unknown&quot;,&quot;discontinuation&quot;:{&quot;detail&quot;:&quot;Switched to TP chemotherapy&quot;,&quot;reason&quot;:&quot;Other&quot;},&quot;end_date&quot;:&quot;2021-09-07&quot;,&quot;in_clinical_trial&quot;:&quot;No&quot;,&quot;intent&quot;:&quot;First_line&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;pfs_days&quot;:&quot;41&quot;,&quot;regimen&quot;:&quot;é¡ºé“‚50mgè…¹è…”åŒ–ç–—&quot;,&quot;response_assessment&quot;:{&quot;best_response&quot;:&quot;Unknown&quot;,&quot;ca125_response&quot;:&quot;Unknown&quot;,&quot;response_criteria&quot;:&quot;Unknown&quot;,&quot;response_date&quot;:&quot;Unknown&quot;},&quot;start_date&quot;:&quot;2021-09-06&quot;},{&quot;concurrent_bevacizumab&quot;:&quot;No&quot;,&quot;cycles_completed&quot;:&quot;6&quot;,&quot;cycles_planned&quot;:&quot;6&quot;,&quot;discontinuation&quot;:{&quot;detail&quot;:&quot;Completed 6 cycles&quot;,&quot;reason&quot;:&quot;Completed&quot;},&quot;end_date&quot;:&quot;2022-03-22&quot;,&quot;in_clinical_trial&quot;:&quot;No&quot;,&quot;intent&quot;:&quot;First_line&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;pfs_days&quot;:&quot;Unknown&quot;,&quot;regimen&quot;:&quot;TP&quot;,&quot;response_assessment&quot;:{&quot;best_response&quot;:&quot;Unknown&quot;,&quot;ca125_response&quot;:&quot;Unknown&quot;,&quot;response_criteria&quot;:&quot;Unknown&quot;,&quot;response_date&quot;:&quot;Unknown&quot;},&quot;start_date&quot;:&quot;2021-10-18&quot;},{&quot;concurrent_bevacizumab&quot;:&quot;No&quot;,&quot;cycles_completed&quot;:&quot;Unknown&quot;,&quot;cycles_planned&quot;:&quot;Unknown&quot;,&quot;discontinuation&quot;:{&quot;detail&quot;:&quot;Temporarily stopped due to adverse reactions and low platelets; restarted 2022-05-23; held 3 weeks around hernia repair; currently continuing&quot;,&quot;reason&quot;:&quot;Other&quot;},&quot;end_date&quot;:&quot;Unknown&quot;,&quot;in_clinical_trial&quot;:&quot;No&quot;,&quot;intent&quot;:&quot;Maintenance&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;pfs_days&quot;:&quot;Unknown&quot;,&quot;regimen&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;,&quot;response_assessment&quot;:{&quot;best_response&quot;:&quot;Unknown&quot;,&quot;ca125_response&quot;:&quot;Unknown&quot;,&quot;response_criteria&quot;:&quot;Unknown&quot;,&quot;response_date&quot;:&quot;Unknown&quot;},&quot;start_date&quot;:&quot;2022-04-Unknown&quot;}],&quot;MAINTENANCE&quot;:&quot;Yes&quot;,&quot;MAINTENANCE_DETAIL&quot;:{&quot;end_date&quot;:&quot;Unknown&quot;,&quot;given&quot;:&quot;Yes&quot;,&quot;regimens&quot;:[&quot;å°¼æ‹‰å¸•åˆ©&quot;],&quot;start_date&quot;:&quot;2022-04-Unknown&quot;},&quot;NEOADJUVANT&quot;:&quot;Unknown&quot;,&quot;PFI_days&quot;:&quot;Unknown&quot;,&quot;PLATINUM_HISTORY&quot;:[{&quot;PFI_days&quot;:&quot;Unknown&quot;,&quot;end_date&quot;:&quot;2022-03-22&quot;,&quot;evidence&quot;:&quot;TP chemotherapy 6 cycles after primary surgery; no explicit relapse documented.&quot;,&quot;evidence_type&quot;:&quot;Unknown&quot;,&quot;first_relapse_date&quot;:&quot;Unknown&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;start_date&quot;:&quot;2021-10-18&quot;,&quot;status&quot;:&quot;Unknown&quot;}],&quot;PLATINUM_PFI_CURRENT&quot;:&quot;Unknown&quot;,&quot;PLATINUM_STATUS&quot;:&quot;Unknown&quot;,&quot;PLATINUM_STATUS_CURRENT&quot;:&quot;Unknown&quot;,&quot;RELAPSE&quot;:&quot;No&quot;,&quot;RELAPSE_DATE&quot;:{&quot;date&quot;:&quot;Unknown&quot;,&quot;evidence&quot;:&quot;No relapse; pelvic MRI 2022-10-25 showed no abnormal soft tissue in pelvis.&quot;,&quot;type&quot;:&quot;Unknown&quot;},&quot;SCENE&quot;:&quot;Maintenance_surveillance_followup&quot;,&quot;STAGE&quot;:{&quot;stage_basis&quot;:&quot;Unknown&quot;,&quot;stage_system&quot;:&quot;Unknown&quot;,&quot;stage_text&quot;:&quot;Unknown&quot;},&quot;SURGERY_DONE&quot;:{&quot;date&quot;:&quot;2021-08-26&quot;,&quot;performed&quot;:&quot;Yes&quot;,&quot;procedure&quot;:&quot;Radical hysterectomy with bilateral salpingo-oophorectomy, pelvic mass resection, partial rectosigmoid resection, sigmoid colostomy, omentectomy, pelvic lymphadenectomy, appendectomy, paraaortic lymphadenectomy&quot;},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2021-08-26&quot;,&quot;description&quot;:&quot;Primary cytoreductive surgery including radical hysterectomy, bilateral salpingo-oophorectomy, bowel resection, omentectomy, lymphadenectomy, colostomy, appendectomy&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Multiple peritoneal sites and 6/24 lymph nodes positive for carcinoma&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2021-08-26&quot;,&quot;description&quot;:&quot;Pathology confirmed high-grade serous carcinoma of bilateral ovaries with widespread peritoneal involvement and nodal metastases&quot;,&quot;event_type&quot;:&quot;Diagnosis&quot;,&quot;key_result&quot;:&quot;High-grade serous carcinoma, bilateral ovaries; 6/24 lymph nodes positive&quot;,&quot;regimen_or_test&quot;:&quot;Pathology&quot;},{&quot;date&quot;:&quot;2021-09-06&quot;,&quot;description&quot;:&quot;Intraperitoneal chemotherapy with cisplatin 50mg&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Completed over 2021-09-06 and 2021-09-07&quot;,&quot;regimen_or_test&quot;:&quot;é¡ºé“‚50mgè…¹è…”åŒ–ç–—&quot;},{&quot;date&quot;:&quot;2021-10-18&quot;,&quot;description&quot;:&quot;Started TP chemotherapy, planned 6 cycles&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Completed 6 cycles, last on 2022-03-22&quot;,&quot;regimen_or_test&quot;:&quot;TP&quot;},{&quot;date&quot;:&quot;2022-03-22&quot;,&quot;description&quot;:&quot;Last cycle of TP chemotherapy&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Adjuvant chemotherapy completed&quot;,&quot;regimen_or_test&quot;:&quot;TP&quot;},{&quot;date&quot;:&quot;2022-04-18&quot;,&quot;description&quot;:&quot;Complete blood count showing thrombocytopenia&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;PLT:33&quot;,&quot;regimen_or_test&quot;:&quot;Blood routine&quot;},{&quot;date&quot;:&quot;2022-04-26&quot;,&quot;description&quot;:&quot;Stopped niraparib due to strong adverse reactions&quot;,&quot;event_type&quot;:&quot;Other&quot;,&quot;key_result&quot;:&quot;Maintenance paused&quot;,&quot;regimen_or_test&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;},{&quot;date&quot;:&quot;2022-05-23&quot;,&quot;description&quot;:&quot;Restarted niraparib 1# qd&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Maintenance resumed&quot;,&quot;regimen_or_test&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;},{&quot;date&quot;:&quot;2022-06-24&quot;,&quot;description&quot;:&quot;Abdominal wall hernia repair at Zhongshan Hospital&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Niraparib held for 3 weeks around surgery&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-09-27&quot;,&quot;description&quot;:&quot;CT chest/abdomen showing small bilateral pleural effusions improved; pulmonary AV fistula and nodules similar to prior&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;No new malignant findings reported; abdominal details deferred&quot;,&quot;regimen_or_test&quot;:&quot;CT&quot;},{&quot;date&quot;:&quot;2022-10-08&quot;,&quot;description&quot;:&quot;CT showing liver segment VII hemangioma and left renal cyst, stable&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;No new findings; chest to correlate with other exams&quot;,&quot;regimen_or_test&quot;:&quot;CT&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;Pelvic MRI after ovarian cancer surgery&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;No abnormal soft tissue in pelvis; follow-up recommended&quot;,&quot;regimen_or_test&quot;:&quot;MR&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;Zhongshan Hospital evaluation: incisional hernia, low-density lesion in right liver lobe&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Blood count and liver/kidney function generally acceptable&quot;,&quot;regimen_or_test&quot;:&quot;Imaging&quot;},{&quot;date&quot;:&quot;2023-01-09&quot;,&quot;description&quot;:&quot;Recent blood routine showed platelet count 34 (year not fully specified)&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;PLT:34 (interpreted from &#x27;PLT:342022.5.23èµ·æ¢å¤&#x27;, year unclear)&quot;,&quot;regimen_or_test&quot;:&quot;Blood routine&quot;}]},&quot;VISIT_DATE&quot;:&quot;2023-01-09&quot;,&quot;first_relapse_date&quot;:&quot;Unknown&quot;,&quot;last_platinum_end_date&quot;:&quot;2022-03-22&quot;},&quot;CLINICAL_TRIALS&quot;:[],&quot;LAB_TRENDS&quot;:{&quot;labs&quot;:[{&quot;analyte&quot;:&quot;Other&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-04-18&quot;,&quot;flag&quot;:&quot;â†“&quot;,&quot;value&quot;:&quot;PLT:33&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-04-18&quot;,&quot;flag&quot;:&quot;â†“&quot;,&quot;value&quot;:&quot;PLT:33&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;Unknown&quot;}],&quot;milestones&quot;:[{&quot;date&quot;:&quot;2021-08-26&quot;,&quot;description&quot;:&quot;Primary debulking surgery for ovarian cancer&quot;,&quot;type&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2021-10-18&quot;,&quot;description&quot;:&quot;Started TP chemotherapy&quot;,&quot;type&quot;:&quot;ChemoStart&quot;},{&quot;date&quot;:&quot;2022-03-22&quot;,&quot;description&quot;:&quot;Completed TP chemotherapy&quot;,&quot;type&quot;:&quot;ChemoEnd&quot;},{&quot;date&quot;:&quot;2022-04-18&quot;,&quot;description&quot;:&quot;Thrombocytopenia (PLT 33) on blood routine&quot;,&quot;type&quot;:&quot;Other&quot;}]},&quot;MED_ONC&quot;:{&quot;current_regimen&quot;:{&quot;cycle_info&quot;:&quot;Continuous oral maintenance; temporarily stopped 2022-04-26 and around 2022-06-24 surgery; currently continuing&quot;,&quot;last_admin_date&quot;:&quot;Unknown&quot;,&quot;name&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;},&quot;genetic_testing&quot;:{&quot;germline&quot;:[],&quot;somatic&quot;:[&quot;HRD&quot;]},&quot;monitoring_points&quot;:[{&quot;drug_or_class&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;,&quot;monitoring&quot;:[&quot;Monitor platelet count due to prior thrombocytopenia&quot;]}],&quot;planned_next_regimen&quot;:&quot;Unknown&quot;,&quot;prior_systemic_therapies&quot;:[&quot;é¡ºé“‚50mgè…¹è…”åŒ–ç–—&quot;,&quot;TP&quot;]},&quot;NUC_MED&quot;:{&quot;studies&quot;:[]},&quot;PATHOLOGY&quot;:{&quot;specimens&quot;:[{&quot;components&quot;:[&quot;High-grade serous carcinoma&quot;,&quot;Myometrial leiomyomas&quot;,&quot;Chronic cervicitis&quot;],&quot;date&quot;:&quot;2021-08-26&quot;,&quot;diagnosis&quot;:&quot;Adenocarcinoma consistent with high-grade serous carcinoma&quot;,&quot;grade&quot;:&quot;High-grade&quot;,&quot;ihc&quot;:[],&quot;involvement_sites&quot;:[&quot;Left ovary&quot;,&quot;Right ovary&quot;,&quot;Left fallopian tube&quot;,&quot;Right fallopian tube&quot;,&quot;Uterine myometrium&quot;,&quot;Pelvic and abdominal peritoneum&quot;,&quot;Partial rectosigmoid colon from serosa to superficial muscle&quot;,&quot;Omentum&quot;,&quot;Left paracolic gutter peritoneum&quot;,&quot;Small bowel mesentery&quot;,&quot;Sigmoid mesentery&quot;,&quot;Appendiceal serosa&quot;,&quot;Pelvic lymph nodes&quot;,&quot;Para-aortic and mesenteric lymph nodes (some positive)&quot;],&quot;laterality&quot;:&quot;Bilateral ovarian involvement&quot;,&quot;molecular&quot;:[{&quot;result&quot;:&quot;Positive&quot;,&quot;test&quot;:&quot;HRD&quot;}],&quot;raw_text&quot;:&quot;æœ¯åç—…ç†ï¼šæ ‡æœ¬ç±»å‹:æ‰©å¤§å­å®«+åŒé™„ä»¶+å·¨å¤§ç›†å—+éƒ¨åˆ†ç›´ä¹™ç»“è‚ +ç›†è…¹è…”å¤šç—…ç¶è‚¿ç˜¤å¤§å°:å·¦ä¾§ï¼š3.5Ã—2Ã—1.5cmï¼›å³ä¾§ï¼š6Ã—5.5Ã—4.5cmè‚¿ç˜¤ä¾§åˆ«:åŒä¾§ç—…ç†ç±»å‹:è…ºç™Œï¼Œç»“åˆå…ç–«ç»„åŒ–ç»“æœï¼ˆI2021-07819ï¼‰ï¼Œç¬¦åˆé«˜çº§åˆ«æµ†æ¶²æ€§ç™Œã€‚å…¶ä»–éƒ¨ä½æƒ…å†µ:å·¦è¾“åµç®¡:è§ç™Œç´¯åŠå³è¾“åµç®¡:è§ç™Œç´¯åŠå­å®«å†…è†œ:èç¼©æ”¹å˜å®«é¢ˆ:æ…¢æ€§ç‚å­å®«è‚Œå±‚:è§ç™Œç´¯åŠï¼›è‚Œå£é—´å¹³æ»‘è‚Œç˜¤ï¼ˆå¤šæšï¼Œç›´å¾„0.5-2cmï¼‰ç›†è…¹è…”å¤šéƒ¨ä½ç—…ç¶:ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ ï¼‰è§ç™Œç´¯åŠï¼Œè‡ªæµ†è†œå±‚æµ¸æ¶¦è‡³æµ…è‚Œå±‚ï¼Œè‚ ç®¡ä¸¤åˆ‡ç¼˜æœªè§ç™Œç´¯åŠã€‚ï¼ˆå¤§ç½‘è†œã€å¤§ç½‘è†œåŠç›†è…”è‚¿å—ã€å·¦ä¾§ç»“è‚ æ—æ²Ÿè…¹è†œã€å°è‚ ç³»è†œè‚¿ç˜¤ã€ä¹™çŠ¶ç»“è‚ ç³»è†œè‚¿ç˜¤ï¼‰è§ç™Œç´¯åŠ.ï¼ˆé˜‘å°¾åŠå‘¨å›´è‚¿å—ï¼‰ æµ†è†œå±‚è§ç™Œç´¯åŠã€‚å…¶ä»–:é€æ£€æ·‹å·´ç»“ï¼ˆ6/24ï¼‰è§ç™Œè½¬ç§»ï¼Œå…¶ä¸­ï¼šå·¦ç›†è…”æ·‹å·´ç»“ï¼ˆ1/4ï¼‰ï¼›å³ç›†è…”æ·‹å·´ç»“ï¼ˆ3/8ï¼‰ï¼›è…¹ä¸»è‚ ç³»è†œä¸‹æ–¹æ·‹å·´ç»“ï¼ˆ1/4ï¼‰ï¼› è‚ ç³»è†œä¸‹åŠ¨è„‰ä¸Šæ–¹æ·‹å·´ç»“ï¼ˆ1/2ï¼‰ï¼›è…¹ä¸»åŠ¨è„‰æ—æ·‹å·´ç»“ï¼ˆ0/6ï¼‰ã€‚&quot;,&quot;sample_type&quot;:&quot;Surgical resection&quot;,&quot;site&quot;:&quot;Uterus, bilateral adnexa, pelvic mass, rectosigmoid colon, peritoneum, omentum, appendix, lymph nodes&quot;,&quot;tumor_size&quot;:&quot;Left ovary 3.5Ã—2Ã—1.5cm; right ovary 6Ã—5.5Ã—4.5cm&quot;,&quot;uncertainty_or_missing&quot;:[&quot;FIGO stage not provided&quot;,&quot;IHC panel details not provided&quot;]}]},&quot;RADIOLOGY&quot;:{&quot;next_imaging_plan&quot;:{&quot;modality&quot;:&quot;Unknown&quot;,&quot;timing&quot;:&quot;Unknown&quot;},&quot;studies&quot;:[{&quot;anatomic_sites&quot;:[&quot;Lung&quot;,&quot;Pleura&quot;,&quot;Chest&quot;],&quot;date&quot;:&quot;2022-09-27&quot;,&quot;findings&quot;:[&quot;Right upper lung arteriovenous fistula similar to prior&quot;,&quot;Right upper lung apical segment small nodule similar to prior&quot;,&quot;Left upper lung scattered tiny nodules&quot;,&quot;Small bilateral pleural effusions decreased compared with prior&quot;,&quot;Scattered chronic inflammatory and fibrotic changes in lungs&quot;,&quot;Atelectasis improved&quot;,&quot;Nodule at right cardiophrenic angle less apparent&quot;],&quot;impression&quot;:&quot;Pulmonary AV fistula and nodules unchanged; pleural effusions and atelectasis improved&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Improved&quot;},{&quot;anatomic_sites&quot;:[&quot;Liver&quot;,&quot;Kidney&quot;,&quot;Spine&quot;],&quot;date&quot;:&quot;2022-10-08&quot;,&quot;findings&quot;:[&quot;Hemangioma in liver right lobe segment VII similar to prior&quot;,&quot;Left renal cyst similar to prior&quot;,&quot;Localized uneven sclerotic change in lumbar vertebrae similar to prior&quot;],&quot;impression&quot;:&quot;Stable hemangioma and renal cyst; spinal sclerosis unchanged; chest findings to correlate with other exams&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Stable&quot;},{&quot;anatomic_sites&quot;:[&quot;Pelvis&quot;],&quot;date&quot;:&quot;2022-10-25&quot;,&quot;findings&quot;:[&quot;Postoperative changes after ovarian cancer surgery&quot;,&quot;No abnormal soft tissue mass in pelvis&quot;],&quot;impression&quot;:&quot;No pelvic recurrence; follow-up recommended&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Stable&quot;}]},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2021-08-26&quot;,&quot;description&quot;:&quot;Primary cytoreductive surgery including radical hysterectomy, bilateral salpingo-oophorectomy, bowel resection, omentectomy, lymphadenectomy, colostomy, appendectomy&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Multiple peritoneal sites and 6/24 lymph nodes positive for carcinoma&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2021-08-26&quot;,&quot;description&quot;:&quot;Pathology confirmed high-grade serous carcinoma of bilateral ovaries with widespread peritoneal involvement and nodal metastases&quot;,&quot;event_type&quot;:&quot;Diagnosis&quot;,&quot;key_result&quot;:&quot;High-grade serous carcinoma, bilateral ovaries; 6/24 lymph nodes positive&quot;,&quot;regimen_or_test&quot;:&quot;Pathology&quot;},{&quot;date&quot;:&quot;2021-09-06&quot;,&quot;description&quot;:&quot;Intraperitoneal chemotherapy with cisplatin 50mg&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Completed over 2021-09-06 and 2021-09-07&quot;,&quot;regimen_or_test&quot;:&quot;é¡ºé“‚50mgè…¹è…”åŒ–ç–—&quot;},{&quot;date&quot;:&quot;2021-10-18&quot;,&quot;description&quot;:&quot;Started TP chemotherapy, planned 6 cycles&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Completed 6 cycles, last on 2022-03-22&quot;,&quot;regimen_or_test&quot;:&quot;TP&quot;},{&quot;date&quot;:&quot;2022-03-22&quot;,&quot;description&quot;:&quot;Last cycle of TP chemotherapy&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Adjuvant chemotherapy completed&quot;,&quot;regimen_or_test&quot;:&quot;TP&quot;},{&quot;date&quot;:&quot;2022-04-18&quot;,&quot;description&quot;:&quot;Complete blood count showing thrombocytopenia&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;PLT:33&quot;,&quot;regimen_or_test&quot;:&quot;Blood routine&quot;},{&quot;date&quot;:&quot;2022-04-26&quot;,&quot;description&quot;:&quot;Stopped niraparib due to strong adverse reactions&quot;,&quot;event_type&quot;:&quot;Other&quot;,&quot;key_result&quot;:&quot;Maintenance paused&quot;,&quot;regimen_or_test&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;},{&quot;date&quot;:&quot;2022-05-23&quot;,&quot;description&quot;:&quot;Restarted niraparib 1# qd&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Maintenance resumed&quot;,&quot;regimen_or_test&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;},{&quot;date&quot;:&quot;2022-06-24&quot;,&quot;description&quot;:&quot;Abdominal wall hernia repair at Zhongshan Hospital&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Niraparib held for 3 weeks around surgery&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-09-27&quot;,&quot;description&quot;:&quot;CT chest/abdomen showing small bilateral pleural effusions improved; pulmonary AV fistula and nodules similar to prior&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;No new malignant findings reported; abdominal details deferred&quot;,&quot;regimen_or_test&quot;:&quot;CT&quot;},{&quot;date&quot;:&quot;2022-10-08&quot;,&quot;description&quot;:&quot;CT showing liver segment VII hemangioma and left renal cyst, stable&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;No new findings; chest to correlate with other exams&quot;,&quot;regimen_or_test&quot;:&quot;CT&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;Pelvic MRI after ovarian cancer surgery&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;No abnormal soft tissue in pelvis; follow-up recommended&quot;,&quot;regimen_or_test&quot;:&quot;MR&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;Zhongshan Hospital evaluation: incisional hernia, low-density lesion in right liver lobe&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Blood count and liver/kidney function generally acceptable&quot;,&quot;regimen_or_test&quot;:&quot;Imaging&quot;},{&quot;date&quot;:&quot;2023-01-09&quot;,&quot;description&quot;:&quot;Recent blood routine showed platelet count 34 (year not fully specified)&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;PLT:34 (interpreted from &#x27;PLT:342022.5.23èµ·æ¢å¤&#x27;, year unclear)&quot;,&quot;regimen_or_test&quot;:&quot;Blood routine&quot;}]},&quot;TOXICITIES&quot;:[{&quot;attribution&quot;:&quot;Probable&quot;,&quot;dose_modification&quot;:&quot;Yes&quot;,&quot;onset_date&quot;:&quot;2022-04-18&quot;,&quot;outcome&quot;:&quot;Resolved&quot;,&quot;related_line&quot;:&quot;1L&quot;,&quot;related_regimen&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;,&quot;severity&quot;:&quot;Severe&quot;,&quot;toxicity&quot;:&quot;Strong adverse reaction to niraparib with thrombocytopenia (PLT 33)&quot;}]}</pre>
      </details>
    </div>
  </div>

  <details class="mt" open>
    <summary>Clinical Trial Recommendation</summary>
    <pre>Trial Recommendation:
- id: None
- name: None
- Reason: Patient is currently on first-line maintenance therapy with niraparib without documented progression or recurrence, and all available trials require prior treatment failure, disease progression, or advanced/metastatic disease with failed standard therapy.
- Missing eligibility confirmations (0-2 items):
  - None</pre>
    <div class="hint">Shown only when the trial matcher produced a recommendation.</div>
  </details>

  <details class="mt" open>
    <summary>ğŸ“‹ MDT Discussion Summary (Assistant)</summary>
    <pre>## MDT Summary

### Key Knowledge
- Stage IIIC high-grade serous ovarian carcinoma, HRD-positive, BRCA1/2 negative
- Currently on 1L niraparib maintenance therapy with good tolerance
- Labs stable: PLT 145Ã—10â¹/L, CA125 6.45 U/ml, normal liver/renal function
- Pelvic MRI (2022-10-25): no evidence of recurrence post-surgery
- Right upper lung AV fistula and stable 4mm nodule; improved bilateral pleural effusions
- All specialists endorse continued PARP inhibitor maintenance per HRD-positive guidelines

### Controversies
- None identified; unanimous agreement on continuing niraparib maintenance and surveillance strategy

### Missing Info
- IHC panel details and formal FIGO staging documentation pending completion
- No PET-CT available; reserved for equivocal future imaging findings

### Working Plan
- Continue niraparib maintenance per HRD-positive status and consensus guidelines
- Schedule pelvic MRI and CA125 surveillance Q3-4 months per standard intervals
- CT follow-up for right upper lung nodule and AV fistula in 3-6 months
- Complete IHC panel documentation and formal FIGO staging for comprehensive pathologic records
- Consider PET-CT only if future conventional imaging becomes equivocal for recurrence</pre>
    <div class="hint">Structured summary of Key Knowledge, Controversies, Missing Info, and Working Plan.</div>
  </details>

  <details class="mt" open>
    <summary>Expert Debate (Round Ã— Turn)</summary>
    <div class='warn'>No expert-to-expert messages were emitted.</div>
    <div class="hint">Only includes messages that were actually emitted (non-empty).</div>
  </details>

  <details class="mt">
    <summary>Initial Expert Opinions (raw)</summary>
    <pre>{
  &quot;chair&quot;: &quot;- Current PLT 145 [@20230109|5600622 | LAB] shows recovery; CA125 6.45 normal [@20230109|9701878 | LAB]; continue niraparib maintenance monitoring.\n\n- HRD-positive status [@OH2201222 | Genomics] supports ongoing PARP inhibitor maintenance per guidelines [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8].\n\n- Pelvic MRI shows no recurrence [@2022-10-25|MR | MR]; recommend updated imaging and CA125 surveillance per standard follow-up intervals.&quot;,
  &quot;oncologist&quot;: &quot;- Patient on 1L niraparib maintenance with HRD-positive status; continue maintenance per consensus recommendations [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024 | Page 10].\n\n- Current labs show recovered platelets (145Ã—10â¹/L), normal liver/renal function, CA125 6.45 U/mlâ€”no toxicity concern [@20230109|5600622 | LAB] [@20230109|9701878 | LAB].\n\n- BRCA1/2 negative per comprehensive NGS; HRD-positive supports ongoing PARP inhibitor benefit [@OH2201222 | Genomics] [@guideline:esmo_cpg_epithelialovarian_2023 | Page 7].&quot;,
  &quot;radiologist&quot;: &quot;- Pelvic MRI (2022-10-25) shows no recurrence: no abnormal soft tissue mass post-ovarian cancer surgery [@2022-10-25|MR | MR]\n\n- Right upper lung AV fistula and stable 4mm nodule unchanged; bilateral pleural effusions improved [@2022-09-27|CT | CT]\n\n- Imaging surveillance should continue per guidelines for post-treatment ovarian cancer monitoring [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]&quot;,
  &quot;pathologist&quot;: &quot;- High-grade serous carcinoma confirmed bilaterally with HRD-positive status; BRCA1/2 negative on comprehensive testing [@OH2201222 | Genomics]\n\n- HRD positivity supports PARP inhibitor eligibility for maintenance therapy per current guidelines [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 7]\n\n- IHC panel details and formal FIGO staging documentation needed for complete pathologic assessment&quot;,
  &quot;nuclear&quot;: &quot;- No PET-CT data available in provided reports; metabolic assessment cannot be performed for staging or recurrence evaluation.\n\n- Pelvic MRI shows no recurrence post-ovarian cancer surgery; recommend follow-up [@2022-10-25|MR | MR].\n\n- PET-CT indicated for suspected recurrence when conventional imaging is equivocal [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15].&quot;
}</pre>
  </details>

  <details class="mt">
    <summary>Final Refined Plans (per round, raw)</summary>
    <pre>{
  &quot;Round 1&quot;: {
    &quot;chair&quot;: &quot;- Continue niraparib maintenance per HRD-positive status [@OH2201222 | Genomics]; supported by guidelines [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8].\n\n- PLT 145, CA125 6.45 [@20230109|5600622 | LAB] [@20230109|9701878 | LAB] confirm stable disease; schedule imaging Q3-4 months.\n\n- Pelvic MRI no recurrence [@2022-10-25|MR | MR]; obtain formal FIGO staging documentation for completeness.&quot;,
    &quot;oncologist&quot;: &quot;- Continue niraparib maintenance for HRD-positive disease; supported by consensus guidelines for PARP inhibitor maintenance [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024 | Page 10].\n\n- Labs stable with CA125 6.45 U/ml, PLT 145Ã—10â¹/L; continue routine surveillance per maintenance protocol [@20230109|9701878 | LAB] [@20230109|5600622 | LAB].\n\n- Schedule pelvic MRI and CA125 at standard intervals; consider PET-CT if future imaging equivocal for recurrence.&quot;,
    &quot;radiologist&quot;: &quot;- Pelvic MRI confirms no recurrence; continue surveillance imaging per NCCN ovarian cancer guidelines [@2022-10-25|MR | MR] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]\n\n- Right upper lung 4mm nodule and AV fistula stable; recommend CT follow-up in 3-6 months [@2022-09-27|CT | CT]\n\n- Consider PET-CT if future imaging equivocal for recurrence, per MDT discussion consensus&quot;,
    &quot;pathologist&quot;: &quot;- HRD-positive, BRCA1/2-negative status confirmed; supports continued PARP inhibitor maintenance per guidelines [@OH2201222 | Genomics] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 7]\n\n- Recommend completing IHC panel documentation and formal FIGO staging for comprehensive pathologic records\n\n- No pathologic concerns requiring intervention; continue standard surveillance with correlation to imaging/tumor markers&quot;,
    &quot;nuclear&quot;: &quot;- No PET-CT currently available; not indicated unless future imaging shows equivocal findings suggestive of recurrence.\n\n- Pelvic MRI confirms no metabolically relevant recurrence concern at present [@2022-10-25|MR | MR].\n\n- PET-CT should be considered if conventional imaging becomes inconclusive per guidelines [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15].&quot;
  }
}</pre>
  </details>

  <details class="mt" open>
    <summary>Selected Clinical Context</summary>
    <table class='grid'><tr><th>Role</th><th>Lab (n)</th><th>Lab newest</th><th>Imaging (n)</th><th>Imaging newest</th><th>Pathology (n)</th><th>Pathology newest</th><th>Mutation (n)</th><th>Mutation newest</th></tr><tr><td class='mono'>chair</td><td>3</td><td>2023-01-09</td><td>3</td><td>2022-10-25</td><td>0</td><td>-</td><td>1</td><td>2022-01-24</td></tr><tr><td class='mono'>nuclear</td><td>0</td><td>-</td><td>3</td><td>2022-10-25</td><td>0</td><td>-</td><td>0</td><td>-</td></tr><tr><td class='mono'>oncologist</td><td>3</td><td>2023-01-09</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-01-24</td></tr><tr><td class='mono'>pathologist</td><td>0</td><td>-</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-01-24</td></tr><tr><td class='mono'>radiologist</td><td>0</td><td>-</td><td>3</td><td>2022-10-25</td><td>0</td><td>-</td><td>0</td><td>-</td></tr></table>
    <div class="hint">Counts and newest dates per role/report type (including mutation).</div>
    <details class="mt">
      <summary>Raw Context (JSON)</summary>
      <pre>{
  &quot;lab&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;20230109|5600622&quot;,
        &quot;date&quot;: &quot;2023-01-09T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ä¸­æ€§ç²’ç»†èƒ% 62.0 % (GRAN)\nPLTåˆ†å¸ƒå®½åº¦ 10 % (PDW)\nå—œç¢±æ€§ç»†èƒæ•° 0.06 *10^9/L (BASO#)\nå—œç¢±æ€§ç»†èƒ% 1.00 % (BASO)\næ·‹å·´ç»†èƒ% 28.8 % (LYM)\nå•æ ¸ç»†èƒ% 7.5 % (MID)\nå—œé…¸æ€§ç»†èƒæ•° 0.04 *10^9/L (EOS#)\nå—œé…¸æ€§ç»†èƒ% 0.70 % (EOS)\nå¹³å‡PLTå®¹ç§¯ 9.4 fl (MPV)\nä¸­æ€§æ·‹å·´æ¯”å€¼ 2.18 nan (NL)\nçº¢ç»†èƒè®¡æ•° 3.96 *10^12/L (RBC)\nè¡€å°æ¿è®¡æ•° 145 *10^9/L (PLT)\nRBCåˆ†å¸ƒå®½åº¦-CV 11.8 % (RDWCV)\nçº¢ç»†èƒæ¯”ç§¯ 37.7 % (HCT)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½é‡ 31.6 pg (MCH)\næ·‹å·´ç»†èƒæ•° 1.7 *10^9/L (LYM#)\nä¸­æ€§ç²’ç»†èƒæ•° 3.7 *10^9/L (GRAN#)\nç™½ç»†èƒè®¡æ•° 6.0 *10^9/L (WBC)\nè¡€çº¢è›‹ç™½é‡ 125 g/l (HGB)\nå¹³å‡çº¢ç»†èƒä½“ç§¯ 95.2 fl (MCV)\nè‡ªåŠ¨å®¡æ ¸æ ‡å¿— ACCEPT nan (VFLAG)\nå•æ ¸ç»†èƒæ•° 0.5 *10^9/L (MID#)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½æµ“åº¦ 332.0 g/l (MCHC)\nè¡€å°æ¿å‹ç§¯ 0.14 % (PCT)\nRBCåˆ†å¸ƒå®½åº¦-SD 41 nan (RDWSD)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230109|8300382&quot;,
        &quot;date&quot;: &quot;2023-01-09T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;Î³-è°·æ°¨é…°åŸºè½¬ç§»é…¶ 24 U/L (GGT)\nå°¿ç´  4.65 mmol/l (UREA)\nä¹³é…¸è„±æ°¢é…¶ 267 U/L (LDH)\nä¸™æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 14.1 U/l (ALT)\nè‚Œé… 68 umol/l (CRE)\nç™½çƒæ¯”ä¾‹ 1.87 nan (A/G)\nç¢±æ€§ç£·é…¸é…¶ 96.3 U/L (ALP)\nå‰ç™½è›‹ç™½ 234 mg/L (PA)\né—´æ¥èƒ†çº¢ç´  5.0 umol/L (IBIL)\næ€»èƒ†çº¢ç´  9.6 umol/l (TBIL)\nè°·æ°¨é…¸è„±æ°¢é…¶ 2.4 U/L (GLDH)\nç›´æ¥èƒ†çº¢ç´  4.6 umol/l (DBIL)\næ¸¸ç¦»è„‚è‚ªé…¸ 0.68 mmol/L (NEFA)\nå¤©å†¬æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 14.5 U/L (AST)\nå°¿é…¸ 242 umol/l (UA)\nç™½è›‹ç™½ 45.7 g/l (ALB)\næ€»è›‹ç™½ 70.1 g/l (TP)\nè°·è‰åŒå·¥é…¶ 8.3 U/L (ASTM)\nçƒè›‹ç™½ 24.4 g/l (GELO)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230109|9701878&quot;,
        &quot;date&quot;: &quot;2023-01-09T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ç³–é“¾æŠ—åŸ125 6.45 U/ml (CA125)\näººé™„ç¾è›‹ç™½4 78.30 pmol/L (HE4)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼ 18.17 %(ç»ç»å‰) (ROMA)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼. 10.06 %(ç»ç»å) (ROMA.)&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;20230109|5600622&quot;,
        &quot;date&quot;: &quot;2023-01-09T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ä¸­æ€§ç²’ç»†èƒ% 62.0 % (GRAN)\nPLTåˆ†å¸ƒå®½åº¦ 10 % (PDW)\nå—œç¢±æ€§ç»†èƒæ•° 0.06 *10^9/L (BASO#)\nå—œç¢±æ€§ç»†èƒ% 1.00 % (BASO)\næ·‹å·´ç»†èƒ% 28.8 % (LYM)\nå•æ ¸ç»†èƒ% 7.5 % (MID)\nå—œé…¸æ€§ç»†èƒæ•° 0.04 *10^9/L (EOS#)\nå—œé…¸æ€§ç»†èƒ% 0.70 % (EOS)\nå¹³å‡PLTå®¹ç§¯ 9.4 fl (MPV)\nä¸­æ€§æ·‹å·´æ¯”å€¼ 2.18 nan (NL)\nçº¢ç»†èƒè®¡æ•° 3.96 *10^12/L (RBC)\nè¡€å°æ¿è®¡æ•° 145 *10^9/L (PLT)\nRBCåˆ†å¸ƒå®½åº¦-CV 11.8 % (RDWCV)\nçº¢ç»†èƒæ¯”ç§¯ 37.7 % (HCT)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½é‡ 31.6 pg (MCH)\næ·‹å·´ç»†èƒæ•° 1.7 *10^9/L (LYM#)\nä¸­æ€§ç²’ç»†èƒæ•° 3.7 *10^9/L (GRAN#)\nç™½ç»†èƒè®¡æ•° 6.0 *10^9/L (WBC)\nè¡€çº¢è›‹ç™½é‡ 125 g/l (HGB)\nå¹³å‡çº¢ç»†èƒä½“ç§¯ 95.2 fl (MCV)\nè‡ªåŠ¨å®¡æ ¸æ ‡å¿— ACCEPT nan (VFLAG)\nå•æ ¸ç»†èƒæ•° 0.5 *10^9/L (MID#)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½æµ“åº¦ 332.0 g/l (MCHC)\nè¡€å°æ¿å‹ç§¯ 0.14 % (PCT)\nRBCåˆ†å¸ƒå®½åº¦-SD 41 nan (RDWSD)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230109|8300382&quot;,
        &quot;date&quot;: &quot;2023-01-09T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;Î³-è°·æ°¨é…°åŸºè½¬ç§»é…¶ 24 U/L (GGT)\nå°¿ç´  4.65 mmol/l (UREA)\nä¹³é…¸è„±æ°¢é…¶ 267 U/L (LDH)\nä¸™æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 14.1 U/l (ALT)\nè‚Œé… 68 umol/l (CRE)\nç™½çƒæ¯”ä¾‹ 1.87 nan (A/G)\nç¢±æ€§ç£·é…¸é…¶ 96.3 U/L (ALP)\nå‰ç™½è›‹ç™½ 234 mg/L (PA)\né—´æ¥èƒ†çº¢ç´  5.0 umol/L (IBIL)\næ€»èƒ†çº¢ç´  9.6 umol/l (TBIL)\nè°·æ°¨é…¸è„±æ°¢é…¶ 2.4 U/L (GLDH)\nç›´æ¥èƒ†çº¢ç´  4.6 umol/l (DBIL)\næ¸¸ç¦»è„‚è‚ªé…¸ 0.68 mmol/L (NEFA)\nå¤©å†¬æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 14.5 U/L (AST)\nå°¿é…¸ 242 umol/l (UA)\nç™½è›‹ç™½ 45.7 g/l (ALB)\næ€»è›‹ç™½ 70.1 g/l (TP)\nè°·è‰åŒå·¥é…¶ 8.3 U/L (ASTM)\nçƒè›‹ç™½ 24.4 g/l (GELO)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230109|9701878&quot;,
        &quot;date&quot;: &quot;2023-01-09T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ç³–é“¾æŠ—åŸ125 6.45 U/ml (CA125)\näººé™„ç¾è›‹ç™½4 78.30 pmol/L (HE4)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼ 18.17 %(ç»ç»å‰) (ROMA)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼. 10.06 %(ç»ç»å) (ROMA.)&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;imaging&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-09-27|CT&quot;,
        &quot;date&quot;: &quot;2022-09-27T13:15:38&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2021-09-01ï¼šå³ä¸Šè‚ºåŠ¨è„‰åˆ†æ”¯è¿œç«¯å¢ç²—ä¸”ä¸å³ä¸Šè‚ºé™è„‰åˆ†æ”¯ç›¸é€šï¼Œå³ä¸Šè‚ºé™è„‰åˆ†æ”¯å¢ç²—ï¼ŒåŒå‰ã€‚å³è‚ºå°–æ®µè§å°ç»“èŠ‚åŒå‰ï¼ˆSE206-57ï¼‰ï¼Œçº¦4mmï¼Œå·¦ä¸Šè‚ºæ•£åœ¨å°ç»“èŠ‚ï¼Œå°äº3mmï¼›ä¸¤è‚ºå¶æ•£åœ¨å°æ–‘ç‰‡æ¡ç´¢çŠ¶é«˜å¯†åº¦å½±ï¼›æ°”ç®¡å±…ä¸­ï¼Œæ‰€è§å„æ”¯æ°”ç®¡è…”é€šç•…ï¼Œå¿ƒå½±å¤§å°æ­£å¸¸ï¼Œçºµéš”æœªè§æ˜æ˜¾è‚¿å¤§æ·‹å·´ç»“ã€‚èƒ¸è†œæ— å¢åšï¼Œä¸¤ä¾§èƒ¸è…”å†…å°‘é‡ç§¯æ¶²è¾ƒå‰å¸æ”¶ã€‚å³ä¾§å¿ƒè†ˆè§’å¤„ç»“èŠ‚å½±è¾ƒå‰ä¸æ˜¾ç¤ºã€‚ é™„è§ç”²çŠ¶è…ºä½å¯†åº¦ç»“èŠ‚å½±ã€è‚è„è§ç¨ä½å¯†åº¦ç»“èŠ‚ã€‚ å³ä¸Šè‚ºåŠ¨é™è„‰ç˜˜å¯èƒ½åŒå‰ï¼Œè¯·ç»“åˆä¸´åºŠåŠä¸“é¡¹æ£€æŸ¥ã€‚ å³ä¸Šè‚ºå°–æ®µå°ç»“èŠ‚åŒå‰ï¼Œå·¦ä¸Šè‚ºæ•£åœ¨å°å¾®å°ç»“èŠ‚ï¼Œéšè®¿ã€‚ ä¸¤ä¾§èƒ¸è…”å†…å°‘é‡ç§¯æ¶²è¾ƒå‰å¸æ”¶ï¼›åŒè‚ºæ•£åœ¨æ…¢æ€§ç‚ç—‡åŠçº¤ç»´ï¼Œè‚ºå¶ä¸å¼ è¾ƒå‰å¥½è½¬ã€‚ å³ä¾§å¿ƒè†ˆè§’å¤„ç»“èŠ‚è¾ƒå‰ä¸æ˜æ˜¾ã€‚ ç”²çŠ¶è…ºåŠè…¹éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-09-29|CT&quot;,
        &quot;date&quot;: &quot;2022-09-29T21:44:24&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2021-09-01ï¼šå·¦ä¸‹è…¹é€ ç˜˜å½±ï¼Œè‚å³å¶VIIæ®µç»“èŠ‚è¾ƒå‰ç›¸ä»¿ï¼Œè¾¹ç¼˜ç»“èŠ‚æ ·å¼ºåŒ–ã€‚è‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ï¼Œå·¦è‚¾è§å›Šæ€§ç»“èŠ‚åŒå‰ã€‚åŒä¾§è‚¾ä¸Šè…ºç»“èŠ‚çŠ¶å¢ç²—ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚æ¨ªè†ˆå‰å¼ºåŒ–æ·‹å·´ç»“è¾ƒå‰ä¸æ˜æ˜¾ã€‚è…°æ¤å±€éƒ¨éª¨è´¨ä¸å‡åŒ€è‡´å¯†åŒå‰ã€‚ è‚å³å¶VIIæ®µè¡€ç®¡ç˜¤åŒå‰ã€‚ å·¦è‚¾å›Šè‚¿åŒå‰ã€‚ è…°æ¤å±€éƒ¨éª¨è´¨ä¸å‡åŒ€è‡´å¯†åŒå‰ï¼Œéšè®¿ã€‚ èƒ¸éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-10-25|MR&quot;,
        &quot;date&quot;: &quot;2022-10-25T13:16:31&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2021-8-17ï¼šåµå·¢ç™Œæœ¯åï¼Œé˜´é“æ®‹ç«¯æœªè§æ˜æ˜¾å¢åšï¼Œç›†è…”æœªè§æ˜æ˜¾å¼‚å¸¸ä¿¡å·è‚¿å—ï¼Œç›†ç»„åŠè…¹è‚¡æ²Ÿæ·‹å·´ç»“æœªè§æ˜æ˜¾è‚¿å¤§ï¼Œç›†è…”æœªè§æ˜æ˜¾ç§¯æ¶²ã€‚ åµå·¢ç™Œæœ¯åï¼Œç›®å‰ç›†è…”æœªè§å¼‚å¸¸è½¯ç»„ç»‡å½±ï¼Œè¯·éšè®¿ã€‚&quot;
      }
    ],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-09-27|CT&quot;,
        &quot;date&quot;: &quot;2022-09-27T13:15:38&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2021-09-01ï¼šå³ä¸Šè‚ºåŠ¨è„‰åˆ†æ”¯è¿œç«¯å¢ç²—ä¸”ä¸å³ä¸Šè‚ºé™è„‰åˆ†æ”¯ç›¸é€šï¼Œå³ä¸Šè‚ºé™è„‰åˆ†æ”¯å¢ç²—ï¼ŒåŒå‰ã€‚å³è‚ºå°–æ®µè§å°ç»“èŠ‚åŒå‰ï¼ˆSE206-57ï¼‰ï¼Œçº¦4mmï¼Œå·¦ä¸Šè‚ºæ•£åœ¨å°ç»“èŠ‚ï¼Œå°äº3mmï¼›ä¸¤è‚ºå¶æ•£åœ¨å°æ–‘ç‰‡æ¡ç´¢çŠ¶é«˜å¯†åº¦å½±ï¼›æ°”ç®¡å±…ä¸­ï¼Œæ‰€è§å„æ”¯æ°”ç®¡è…”é€šç•…ï¼Œå¿ƒå½±å¤§å°æ­£å¸¸ï¼Œçºµéš”æœªè§æ˜æ˜¾è‚¿å¤§æ·‹å·´ç»“ã€‚èƒ¸è†œæ— å¢åšï¼Œä¸¤ä¾§èƒ¸è…”å†…å°‘é‡ç§¯æ¶²è¾ƒå‰å¸æ”¶ã€‚å³ä¾§å¿ƒè†ˆè§’å¤„ç»“èŠ‚å½±è¾ƒå‰ä¸æ˜¾ç¤ºã€‚ é™„è§ç”²çŠ¶è…ºä½å¯†åº¦ç»“èŠ‚å½±ã€è‚è„è§ç¨ä½å¯†åº¦ç»“èŠ‚ã€‚ å³ä¸Šè‚ºåŠ¨é™è„‰ç˜˜å¯èƒ½åŒå‰ï¼Œè¯·ç»“åˆä¸´åºŠåŠä¸“é¡¹æ£€æŸ¥ã€‚ å³ä¸Šè‚ºå°–æ®µå°ç»“èŠ‚åŒå‰ï¼Œå·¦ä¸Šè‚ºæ•£åœ¨å°å¾®å°ç»“èŠ‚ï¼Œéšè®¿ã€‚ ä¸¤ä¾§èƒ¸è…”å†…å°‘é‡ç§¯æ¶²è¾ƒå‰å¸æ”¶ï¼›åŒè‚ºæ•£åœ¨æ…¢æ€§ç‚ç—‡åŠçº¤ç»´ï¼Œè‚ºå¶ä¸å¼ è¾ƒå‰å¥½è½¬ã€‚ å³ä¾§å¿ƒè†ˆè§’å¤„ç»“èŠ‚è¾ƒå‰ä¸æ˜æ˜¾ã€‚ ç”²çŠ¶è…ºåŠè…¹éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-09-29|CT&quot;,
        &quot;date&quot;: &quot;2022-09-29T21:44:24&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2021-09-01ï¼šå·¦ä¸‹è…¹é€ ç˜˜å½±ï¼Œè‚å³å¶VIIæ®µç»“èŠ‚è¾ƒå‰ç›¸ä»¿ï¼Œè¾¹ç¼˜ç»“èŠ‚æ ·å¼ºåŒ–ã€‚è‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ï¼Œå·¦è‚¾è§å›Šæ€§ç»“èŠ‚åŒå‰ã€‚åŒä¾§è‚¾ä¸Šè…ºç»“èŠ‚çŠ¶å¢ç²—ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚æ¨ªè†ˆå‰å¼ºåŒ–æ·‹å·´ç»“è¾ƒå‰ä¸æ˜æ˜¾ã€‚è…°æ¤å±€éƒ¨éª¨è´¨ä¸å‡åŒ€è‡´å¯†åŒå‰ã€‚ è‚å³å¶VIIæ®µè¡€ç®¡ç˜¤åŒå‰ã€‚ å·¦è‚¾å›Šè‚¿åŒå‰ã€‚ è…°æ¤å±€éƒ¨éª¨è´¨ä¸å‡åŒ€è‡´å¯†åŒå‰ï¼Œéšè®¿ã€‚ èƒ¸éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-10-25|MR&quot;,
        &quot;date&quot;: &quot;2022-10-25T13:16:31&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2021-8-17ï¼šåµå·¢ç™Œæœ¯åï¼Œé˜´é“æ®‹ç«¯æœªè§æ˜æ˜¾å¢åšï¼Œç›†è…”æœªè§æ˜æ˜¾å¼‚å¸¸ä¿¡å·è‚¿å—ï¼Œç›†ç»„åŠè…¹è‚¡æ²Ÿæ·‹å·´ç»“æœªè§æ˜æ˜¾è‚¿å¤§ï¼Œç›†è…”æœªè§æ˜æ˜¾ç§¯æ¶²ã€‚ åµå·¢ç™Œæœ¯åï¼Œç›®å‰ç›†è…”æœªè§å¼‚å¸¸è½¯ç»„ç»‡å½±ï¼Œè¯·éšè®¿ã€‚&quot;
      }
    ],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-09-27|CT&quot;,
        &quot;date&quot;: &quot;2022-09-27T13:15:38&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2021-09-01ï¼šå³ä¸Šè‚ºåŠ¨è„‰åˆ†æ”¯è¿œç«¯å¢ç²—ä¸”ä¸å³ä¸Šè‚ºé™è„‰åˆ†æ”¯ç›¸é€šï¼Œå³ä¸Šè‚ºé™è„‰åˆ†æ”¯å¢ç²—ï¼ŒåŒå‰ã€‚å³è‚ºå°–æ®µè§å°ç»“èŠ‚åŒå‰ï¼ˆSE206-57ï¼‰ï¼Œçº¦4mmï¼Œå·¦ä¸Šè‚ºæ•£åœ¨å°ç»“èŠ‚ï¼Œå°äº3mmï¼›ä¸¤è‚ºå¶æ•£åœ¨å°æ–‘ç‰‡æ¡ç´¢çŠ¶é«˜å¯†åº¦å½±ï¼›æ°”ç®¡å±…ä¸­ï¼Œæ‰€è§å„æ”¯æ°”ç®¡è…”é€šç•…ï¼Œå¿ƒå½±å¤§å°æ­£å¸¸ï¼Œçºµéš”æœªè§æ˜æ˜¾è‚¿å¤§æ·‹å·´ç»“ã€‚èƒ¸è†œæ— å¢åšï¼Œä¸¤ä¾§èƒ¸è…”å†…å°‘é‡ç§¯æ¶²è¾ƒå‰å¸æ”¶ã€‚å³ä¾§å¿ƒè†ˆè§’å¤„ç»“èŠ‚å½±è¾ƒå‰ä¸æ˜¾ç¤ºã€‚ é™„è§ç”²çŠ¶è…ºä½å¯†åº¦ç»“èŠ‚å½±ã€è‚è„è§ç¨ä½å¯†åº¦ç»“èŠ‚ã€‚ å³ä¸Šè‚ºåŠ¨é™è„‰ç˜˜å¯èƒ½åŒå‰ï¼Œè¯·ç»“åˆä¸´åºŠåŠä¸“é¡¹æ£€æŸ¥ã€‚ å³ä¸Šè‚ºå°–æ®µå°ç»“èŠ‚åŒå‰ï¼Œå·¦ä¸Šè‚ºæ•£åœ¨å°å¾®å°ç»“èŠ‚ï¼Œéšè®¿ã€‚ ä¸¤ä¾§èƒ¸è…”å†…å°‘é‡ç§¯æ¶²è¾ƒå‰å¸æ”¶ï¼›åŒè‚ºæ•£åœ¨æ…¢æ€§ç‚ç—‡åŠçº¤ç»´ï¼Œè‚ºå¶ä¸å¼ è¾ƒå‰å¥½è½¬ã€‚ å³ä¾§å¿ƒè†ˆè§’å¤„ç»“èŠ‚è¾ƒå‰ä¸æ˜æ˜¾ã€‚ ç”²çŠ¶è…ºåŠè…¹éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-09-29|CT&quot;,
        &quot;date&quot;: &quot;2022-09-29T21:44:24&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2021-09-01ï¼šå·¦ä¸‹è…¹é€ ç˜˜å½±ï¼Œè‚å³å¶VIIæ®µç»“èŠ‚è¾ƒå‰ç›¸ä»¿ï¼Œè¾¹ç¼˜ç»“èŠ‚æ ·å¼ºåŒ–ã€‚è‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ï¼Œå·¦è‚¾è§å›Šæ€§ç»“èŠ‚åŒå‰ã€‚åŒä¾§è‚¾ä¸Šè…ºç»“èŠ‚çŠ¶å¢ç²—ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚æ¨ªè†ˆå‰å¼ºåŒ–æ·‹å·´ç»“è¾ƒå‰ä¸æ˜æ˜¾ã€‚è…°æ¤å±€éƒ¨éª¨è´¨ä¸å‡åŒ€è‡´å¯†åŒå‰ã€‚ è‚å³å¶VIIæ®µè¡€ç®¡ç˜¤åŒå‰ã€‚ å·¦è‚¾å›Šè‚¿åŒå‰ã€‚ è…°æ¤å±€éƒ¨éª¨è´¨ä¸å‡åŒ€è‡´å¯†åŒå‰ï¼Œéšè®¿ã€‚ èƒ¸éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-10-25|MR&quot;,
        &quot;date&quot;: &quot;2022-10-25T13:16:31&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2021-8-17ï¼šåµå·¢ç™Œæœ¯åï¼Œé˜´é“æ®‹ç«¯æœªè§æ˜æ˜¾å¢åšï¼Œç›†è…”æœªè§æ˜æ˜¾å¼‚å¸¸ä¿¡å·è‚¿å—ï¼Œç›†ç»„åŠè…¹è‚¡æ²Ÿæ·‹å·´ç»“æœªè§æ˜æ˜¾è‚¿å¤§ï¼Œç›†è…”æœªè§æ˜æ˜¾ç§¯æ¶²ã€‚ åµå·¢ç™Œæœ¯åï¼Œç›®å‰ç›†è…”æœªè§å¼‚å¸¸è½¯ç»„ç»‡å½±ï¼Œè¯·éšè®¿ã€‚&quot;
      }
    ]
  },
  &quot;pathology&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;mutation&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2201222&quot;,
        &quot;date&quot;: &quot;2022-01-24T13:59:34&quot;,
        &quot;raw_text&quot;: &quot;HRD é˜³æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2201222&quot;,
        &quot;date&quot;: &quot;2022-01-24T13:59:34&quot;,
        &quot;raw_text&quot;: &quot;HRD é˜³æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2201222&quot;,
        &quot;date&quot;: &quot;2022-01-24T13:59:34&quot;,
        &quot;raw_text&quot;: &quot;HRD é˜³æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ],
    &quot;nuclear&quot;: []
  }
}</pre>
    </details>
  </details>

  <details class="mt">
    <summary>Guideline + PubMed RAG</summary>
    <h3>RAG Query</h3>
    <pre>High-grade serous ovarian carcinoma with peritoneal carcinomatosis and nodal metastases (6/24 positive), HRD-positive but BRCA1/2-negative, platinum-sensitive post-adjuvant TP chemotherapy, on niraparib maintenance with severe thrombocytopenia (PLT 33-34) requiring dose modification; histology: High-grade serous carcinoma</pre>
    <h3>Evidence Pack (top-k)</h3>
    <pre># GUIDELINE RAG
RAG Evidence Pack (top=5):
[1] score=0.6700 esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 [PAGE 10] [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 10]
    platinum-based ChT followed by niraparib or rucaparib if in CR/PR/NED [I, B]. Consensus: 97% (35) yes, 0% (0) no, 3% (1) abstain (36 voters) Recommendation 13.9: When used as maintenance in patients in CR/PR/NED to platinum-based ChT, olaparib (alone or in combination with bevacizumab) and rucaparibâ€¦
[2] score=0.6601 nccn_ovariancancer_v3_2025__v00000000 [PAGE 15] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]
    based chemotherapy,n preferred for first recurrence (category 1) or Recurrence therapyn,kk and/or Best supportive care (See NCCN Guidelines for Palliative Care) Consider secondary cytoreductive surgeryj,k Immediate platinum-based recurrence therapyn (category 2B) and/or Best supportive care (See NCCâ€¦
[3] score=0.6590 nccn_ovariancancer_v3_2025__v00000000 [PAGE 12] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 12]
    Version 3.2025, 07/16/25 Â© 2025 National Comprehensive Cancer NetworkÂ® (NCCNÂ®), All rights reserved. NCCN GuidelinesÂ® and this illustration may not be reproduced in any form without the express written permission of NCCN. Note: All recommendations are category 2A unless otherwise indicated. NCCN Guiâ€¦
[4] score=0.6542 esmo_cpg_epithelialovarian_2023__v00000000 [PAGE 8] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]
    MCBS v1.1 score: 4; ESMO Scale for Clinical Actionabil- ity of molecular Targets (ESCAT) score: I-A], niraparib for 3 years [ESMO-MCBS v1.1 score: 3; ESCAT score: I-A] or olaparibebevacizumab for 2 years [ESMO- MCBS v1.1 score: 3; ESCAT score: I-A]. o For BRCA1/2-wt/HRD-positive: niraparib for 3 yeaâ€¦
[5] score=0.6541 esmo_cpg_epithelialovarian_2023__v00000000 [PAGE 7] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 7]
    A descriptive OS analysis of SOLO1 at 7-year follow-up60 and the ï¬nal OS analysis of PAOLA-161 have shown a beneï¬t in OS for olaparib in patients with BRCA1/2-mutated tu- mours and olaparibebevacizumab in patients with HRD- positive tumours regardless of BRCA1/2-mut status (see Supplementary Materiaâ€¦

# PUBMED RAG
PUBMED Evidence Pack (top=5):
[1] score=0.7530 PMID 40687421 [@pubmed | 40687421]
    Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review.
    Ovarian cancer (OC) is a common gynecological malignancy, and poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy has significantly prolonged the survival of newly diagnosed or platinum-sensitive recurrent ovarian cancer patients, which has become a new treatment paradigm for ovarian â€¦
[2] score=0.7374 PMID 35359396 [@pubmed | 35359396]
    Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of
    Niraparib, an oral, potent, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, has promising clinical benefit for maintenance treatment of patients with ovarian cancer in partial response to platinum-based chemotherapy, especially in patients with BRCA mutation. In publicly available niâ€¦
[3] score=0.7118 PMID 40777128 [@pubmed | 40777128]
    Correction: Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review.
    [This corrects the article DOI: 10.3389/fonc.2025.1542646.].
[4] score=0.7048 PMID 34938651 [@pubmed | 34938651]
    Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma.
    Ovarian carcinosarcoma (OCS) is a rare, highly aggressive and rapidly progressing malignant tumor with an extremely poor prognosis. So far, due to the low incidence of OCS, there are no large-scale prospective studies exploring the standard care of OCS patients. There is no uniform and effective treâ€¦
[5] score=0.6965 PMID 33376347 [@pubmed | 33376347]
    Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic
    Brain metastases from epithelial ovarian cancer are very rare with an incidence of only 1-2.5%. Many therapeutic methods such as surgery, irradiation and chemotherapy do produce survival benefits, but the overall outcome remains unsatisfactory. The BRCA (breast cancer susceptibility gene) mutation sâ€¦</pre>
    <h3>RAG Raw Hits (JSON)</h3>
    <pre>[
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.6699762940406799,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esgo_esmo_esp_consensus_ovariancancer_2024__v00000000&quot;,
    &quot;page&quot;: 10,
    &quot;text&quot;: &quot;platinum-based ChT followed by niraparib or rucaparib if\nin CR/PR/NED [I, B].\nConsensus: 97% (35) yes, 0% (0) no, 3% (1) abstain (36\nvoters)\nRecommendation 13.9: When used as maintenance in\npatients in CR/PR/NED to platinum-based ChT, olaparib\n(alone or in combination with bevacizumab) and rucaparib\nare recommended for 2 years, and niraparib is recom-\nmended for 3 years [I, A].\nConsensus: 97% (34) yes, 0% (0) no, 3% (1) abstain (35\nvoters)\n14. How should older/frail patients with tubo-ovarian\ncarcinoma be investigated and treated?\nOlder patients are under-represented in clinical trials due\nto their poor performance status (PS) and comorbidities,88\nand their outcomes are poorer.89 Geriatric assessment\ngathers information on functional, mental and nutritional\nstatus, emotional conditions and social support.90 Vulner-\nability scores have been validated in clinical trials.90,91\nSurgery, frequently carried out in an emergency context\nand in unspecialised centres, is often incomplete, with\nhigher\npost-operative\ncomplications.92\nChT\nmay\nbe\nunderutilised.93,94\nRecommendation 14.1: Patients should not be excluded\nfrom diagnostic procedures, clinical trials and speciï¬c&quot;
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.66008460521698,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 15,
    &quot;text&quot;: &quot;based chemotherapy,n\npreferred for first\nrecurrence (category 1)\nor\nRecurrence therapyn,kk\nand/or\nBest supportive care\n(See NCCN Guidelines\nfor Palliative Care)\nConsider\nsecondary\ncytoreductive\nsurgeryj,k\nImmediate platinum-based\nrecurrence therapyn (category 2B)\nand/or\nBest supportive care (See NCCN\nGuidelines for Palliative Care)\nRECURRENCE THERAPY FOR PLATINUM-SENSITIVE DISEASEn,gg,hh,ii\nMaintenance therapy (if PR or CR)\nâ€¢ Useful in certain circumstances:\n\u0017Continue bevacizumab if previously\ntreated with chemotherapy +\nbevacizumab;\nor\n\u0017PARPi therapy (for those with BRCA\n1/2 mutation)ll:\n â—ŠIf not previously used (category 1)\n â—ŠIf disease has not progressed\nduring prior PARPi treatment\nor\nObserve\ngg Data are limited on primary and maintenance therapy for recurrent/persistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated as indicated with\ntumor markers and repeat imaging (with modalities previously used) to document response\nand/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\nkk Localized RT can be considered to palliate symptoms and/or for oligometastatic disease.&quot;
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.658991813659668,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 12,
    &quot;text&quot;: &quot;Version 3.2025, 07/16/25 Â© 2025 National Comprehensive Cancer NetworkÂ® (NCCNÂ®), All rights reserved. NCCN GuidelinesÂ® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nEpithelial Ovarian Cancer/Fallopian Tube Cancer/\nPrimary Peritoneal Cancer\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nCRx/PR\nOV-5\nSTAGE II, III, IVw\nPOST PRIMARY TREATMENT\nHR\ndeficient\nHomologous\nrecombination (HR)\nproficient or status\nunknown\nOlaparib (category 1)\nor\nNiraparib (category 1)\nor\nRucaparib\nor\nObserve for select stage II disease with CR\nObserve (if CR)\nor\nNiraparib (HR deficient)\nor\nRucaparib\nor\nOlaparib (HR deficient) (category 2B)\nor\nTherapy for Persistent Disease or Recurrence (OV-7)\nMonitoring/\nFollow-up (OV-6)\nMonitoring/\nFollow-Up (OV-6)\nMAINTENANCE THERAPYh,n,y\nBevacizumab\nused as part\nof primary\ntherapy\nNo\nbevacizumab\nused during\nprimary\ntherapy\nGermline\nor somatic\nBRCA1/2\nmutation\nBRCA1/2\nwild-type or\nunknownh\nGermline\nor somatic\nBRCA1/2\nmutation\nBRCA1/2\nwild-type or\nunknownh\nBevacizumab + olaparib (category 1)\nor&quot;
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.6541700959205627,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esmo_cpg_epithelialovarian_2023__v00000000&quot;,
    &quot;page&quot;: 8,
    &quot;text&quot;: &quot;MCBS v1.1 score: 4; ESMO Scale for Clinical Actionabil-\nity of molecular Targets (ESCAT) score: I-A], niraparib\nfor 3 years [ESMO-MCBS v1.1 score: 3; ESCAT score:\nI-A] or olaparibebevacizumab for 2 years [ESMO-\nMCBS v1.1 score: 3; ESCAT score: I-A].\no For BRCA1/2-wt/HRD-positive: niraparib for 3 years\n[ESMO-MCBS v1.1 score: 3; ESCAT score: I-A] or\nolaparibebevacizumab for 2 years [ESMO-MCBS v1.1\nscore: 3; ESCAT score: I-A).\n\u0004 Maintenance treatment with either bevacizumab [I, A] or\nniraparib for 3 years [I, B; ESMO-MCBS v1.1 score: 3] can\nbe recommended for HRD-negative tumours, with the\nlatter\nfollowing\ncomplete\nor\npartial\nresponse\nto\nplatinumepaclitaxel ï¬rst-line ChT. The choice of treat-\nment should be based on disease and clinical character-\nistics of the patient.\n\u0004 Maintenance with anti-estrogen therapy after ï¬rst-line\nplatinum-based ChT can be considered in LGSC [IV, B].\nMANAGEMENT OF RECURRENT EOC\nPatient assessment\nUp to 70% of patients with stage III-IV high-grade ovarian\ncancer will relapse within 3 years. Relapse rates for early-\nstage ovarian cancer are much lower.\nSeveral factors need to be assessed when selecting a&quot;
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.6541137099266052,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esmo_cpg_epithelialovarian_2023__v00000000&quot;,
    &quot;page&quot;: 7,
    &quot;text&quot;: &quot;A descriptive OS analysis of SOLO1 at 7-year follow-up60\nand the ï¬nal OS analysis of PAOLA-161 have shown a beneï¬t\nin OS for olaparib in patients with BRCA1/2-mutated tu-\nmours and olaparibebevacizumab in patients with HRD-\npositive tumours regardless of BRCA1/2-mut status (see\nSupplementary Material Section 3, available at https://doi.\norg/10.1016/j.annonc.2023.07.011).\nNon-high-grade serous advanced ovarian cancer. Pacli-\ntaxelecarboplatin is the standard systemic ChT used in\nLGSC, CCC and MC. Multiple retrospective studies, however,\nshowed lower response rates in these histotypes compared\nwith HGSC.62-64 Bevacizumab has shown activity in all his-\ntotypes including those less chemoresponsive, e.g. LGSC or\nCCC.49 The majority of LGSCs have high expression of es-\ntrogen receptor (ER) and progesterone receptor (PgR);\nretrospective studies suggest a possible therapeutic value of\nhormone therapy in the maintenance of newly diagnosed\nadvanced LGSC.65 This intervention is currently under\nevaluation in a prospective RCT (NCT04095364).\nRecommendations\n\u0004 Patients with advanced EOC should be evaluated for PCS\nby a specialised team, with the aim of achieving&quot;
  },
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.7529642384135231,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;40687421&quot;,
    &quot;title&quot;: &quot;Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review.&quot;,
    &quot;abstract&quot;: &quot;Ovarian cancer (OC) is a common gynecological malignancy, and poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance therapy has significantly prolonged the survival of newly diagnosed or platinum-sensitive recurrent ovarian cancer patients, which has become a new treatment paradigm for ovarian cancer. Niraparib is a widely used PARP inhibitor in the clinical setting, and its adverse effects are also a major concern. The common adverse reactions of Niraparib mainly include various hematological adverse reactions (such as thrombocytopenia and anemia), gastrointestinal adverse reactions (such as nausea and vomiting), and fatigue. In previous related reports, thrombocytopenia has been mentioned multiple times, a relatively common adverse reaction of Niraparib. However, there have been no reports of irreversible and persistent thrombocytopenia. This case report describes a 59-year-old woman who developed persistent thrombocytopenia 11 months after adjuvant chemotherapy for stage IIIC high-grade serous ovarian cancer. Despite various treatment measures, the patient&#x27;s platelet count continues to fluctuate and remains low. This is a severe thrombocytopenia that may rare adverse reaction caused by Niraparib. This article adds important information to the scientific literature on potential serious adverse reactions in long-term treatment with Niraparib. It emphasizes the necessity of closely monitoring platelet counts during Niraparib treatment.&quot;,
    &quot;journal&quot;: &quot;Front Oncol&quot;,
    &quot;pub_date&quot;: &quot;2025-01-01&quot;,
    &quot;doi&quot;: &quot;10.3389/fonc.2025.1542646&quot;,
    &quot;impact_factor&quot;: 3.3,
    &quot;similarity&quot;: 0.7529642384135231
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.7374421785088325,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;35359396&quot;,
    &quot;title&quot;: &quot;Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of&quot;,
    &quot;abstract&quot;: &quot;Niraparib, an oral, potent, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, has promising clinical benefit for maintenance treatment of patients with ovarian cancer in partial response to platinum-based chemotherapy, especially in patients with BRCA mutation. In publicly available niraparib treatment-related adverse events, gastrointestinal disorders and hematological toxicities were most commonly reported with manageable safety profile. Herein, we first describe a severe and never-reported pulmonary embolism (PE) associated with the use of niraparib in a patient with BRCA mutation advanced high-grade serous ovarian cancer and received anticoagulant therapy after PE. There have been no reports of PE caused by the use of niraparib in patients with advanced high-grade serous ovarian cancer; knowledge of the occurrence of PE after the use of niraparib may assist other clinicians in managing this rare but potentially serious toxic effect.&quot;,
    &quot;journal&quot;: &quot;Front Oncol&quot;,
    &quot;pub_date&quot;: &quot;2022-01-01&quot;,
    &quot;doi&quot;: &quot;10.3389/fonc.2022.853211&quot;,
    &quot;impact_factor&quot;: 3.3,
    &quot;similarity&quot;: 0.7374421785088325
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.7118336629019619,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;40777128&quot;,
    &quot;title&quot;: &quot;Correction: Severe thrombocytopenia induced by niraparib in ovarian cancer patients: a case report and literature review.&quot;,
    &quot;abstract&quot;: &quot;[This corrects the article DOI: 10.3389/fonc.2025.1542646.].&quot;,
    &quot;journal&quot;: &quot;Front Oncol&quot;,
    &quot;pub_date&quot;: &quot;2025-01-01&quot;,
    &quot;doi&quot;: &quot;10.3389/fonc.2025.1661708&quot;,
    &quot;impact_factor&quot;: 3.3,
    &quot;similarity&quot;: 0.7118336629019619
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.7048006474308194,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;34938651&quot;,
    &quot;title&quot;: &quot;Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma.&quot;,
    &quot;abstract&quot;: &quot;Ovarian carcinosarcoma (OCS) is a rare, highly aggressive and rapidly progressing malignant tumor with an extremely poor prognosis. So far, due to the low incidence of OCS, there are no large-scale prospective studies exploring the standard care of OCS patients. There is no uniform and effective treatment for OCS. Within the development of precision medicine, targeted therapies (such as PARP inhibitors) have been widely used in epithelial ovarian cancer and various other solid tumors. Here, we report a BRCAwt patient with advanced OCS who experienced a second and a third cytoreductive surgery in June 2017 and October 2019 and has been on niraparib maintenance therapy for more than 20 months after receiving second-line and third-line chemotherapy.&quot;,
    &quot;journal&quot;: &quot;Front Oncol&quot;,
    &quot;pub_date&quot;: &quot;2021-01-01&quot;,
    &quot;doi&quot;: &quot;10.3389/fonc.2021.603591&quot;,
    &quot;impact_factor&quot;: 3.3,
    &quot;similarity&quot;: 0.7048006474308194
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.6965115390968533,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;33376347&quot;,
    &quot;title&quot;: &quot;Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic&quot;,
    &quot;abstract&quot;: &quot;Brain metastases from epithelial ovarian cancer are very rare with an incidence of only 1-2.5%. Many therapeutic methods such as surgery, irradiation and chemotherapy do produce survival benefits, but the overall outcome remains unsatisfactory. The BRCA (breast cancer susceptibility gene) mutation status seems to be associated with the development of brain metastases from ovarian cancer and these patients may benefit from treatment with PARP (poly ADP ribose polymerase) inhibitors. Here is a case where a Chinese female patient diagnosed with high-grade serous ovarian cancer with brain metastases was detected to have known germline ATM mutation and somatic BRCA2 mutation. The patient underwent whole brain radiotherapy and systemic chemotherapy, commenced niraparib as maintenance treatment and then presented considerable clinical and radiological response.&quot;,
    &quot;journal&quot;: &quot;Onco Targets Ther&quot;,
    &quot;pub_date&quot;: &quot;2020-01-01&quot;,
    &quot;doi&quot;: &quot;10.2147/OTT.S281302&quot;,
    &quot;impact_factor&quot;: 2.8,
    &quot;similarity&quot;: 0.6965115390968533
  }
]</pre>
    <h3>Evidence Digest (1:1 per RAG result)</h3>
    <pre>- Platinum-based chemotherapy followed by niraparib or rucaparib maintenance is recommended for patients in CR/PR/NED, with 97% consensus support [I, B evidence level] [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 10]

- For platinum-sensitive recurrence, secondary cytoreductive surgery should be considered along with platinum-based recurrence therapy; immediate platinum-based therapy without surgery is category 2B [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]

- All NCCN recommendations for ovarian cancer management are category 2A unless otherwise specified, indicating uniform consensus based on lower-level evidence [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 12]

- For BRCA1/2-mutated tumors: olaparib for 2 years (ESMO-MCBS 4, ESCAT I-A), niraparib for 3 years (ESMO-MCBS 3, ESCAT I-A), or olaparib-bevacizumab for 2 years (ESMO-MCBS 3, ESCAT I-A) are evidence-based maintenance options [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]

- SOLO1 7-year follow-up and PAOLA-1 final analysis demonstrate OS benefit for olaparib in BRCA1/2-mutated tumors and olaparib-bevacizumab in HRD-positive tumors regardless of BRCA status [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 7]

- Severe thrombocytopenia is a recognized adverse event with niraparib maintenance therapy requiring monitoring and potential dose adjustment [@pubmed | 40687421]

- Pulmonary embolism has been reported during niraparib treatment, warranting vigilance for thromboembolic events particularly in patients with additional risk factors [@pubmed | 35359396]

- Hematologic toxicity monitoring remains essential during PARP inhibitor maintenance, with thrombocytopenia being dose-limiting in some patients [@pubmed | 40777128]

- PARP inhibitor maintenance (niraparib) may provide benefit in rare histologic subtypes including ovarian carcinosarcoma, though evidence is limited to case reports [@pubmed | 34938651]

- Niraparib maintenance has shown activity in patients with germline ATM mutations and brain metastases, suggesting potential benefit beyond BRCA-mutated populations [@pubmed | 33376347]</pre>
  </details>

  <details class='mt mermaid-container' open><summary>Pipeline Flow</summary><div class='mermaid-chart'>flowchart TD
  A[Load Case + Fingerprint] --> B[Load Reports]
  B --> C[Report Selection per Role]
  C --> D[Guideline+PubMed RAG]
  D --> E[Init Specialist Agents]
  E --> F[MDT Discussion Engine]
  F --> G[Trial Matching]
  G --> H[Final Chair Output]
  H --> I[Save Logs]</div></details>

  <details class="mt">
    <summary>Trace Events (JSON)</summary>
    <pre>[
  {
    &quot;ts&quot;: &quot;2026-01-22T18:35:50.125084&quot;,
    &quot;event&quot;: &quot;pipeline_start&quot;,
    &quot;payload&quot;: {
      &quot;visit_time&quot;: &quot;2023-01-09 09:23:13.113000&quot;,
      &quot;meta_info&quot;: &quot;310103195705270044&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:35:50.126109&quot;,
    &quot;event&quot;: &quot;case_fingerprint&quot;,
    &quot;payload&quot;: {
      &quot;case_fingerprint&quot;: &quot;fa2f34f1e565&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:35:50.690489&quot;,
    &quot;event&quot;: &quot;reports_loaded&quot;,
    &quot;payload&quot;: {
      &quot;lab_n&quot;: 152,
      &quot;img_n&quot;: 24,
      &quot;path_n&quot;: 0,
      &quot;mut_n&quot;: 1,
      &quot;cutoff_dt&quot;: &quot;2023-01-10 09:23:13&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:35:58.362693&quot;,
    &quot;event&quot;: &quot;reports_selected&quot;,
    &quot;payload&quot;: {
      &quot;lab&quot;: {
        &quot;chair&quot;: [
          &quot;20230109|5600622|2023-01-09&quot;,
          &quot;20230109|8300382|2023-01-09&quot;,
          &quot;20230109|9701878|2023-01-09&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;20230109|5600622|2023-01-09&quot;,
          &quot;20230109|8300382|2023-01-09&quot;,
          &quot;20230109|9701878|2023-01-09&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;imaging&quot;: {
        &quot;chair&quot;: [
          &quot;2022-09-27|CT|2022-09-27&quot;,
          &quot;2022-09-29|CT|2022-09-29&quot;,
          &quot;2022-10-25|MR|2022-10-25&quot;
        ],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [
          &quot;2022-09-27|CT|2022-09-27&quot;,
          &quot;2022-09-29|CT|2022-09-29&quot;,
          &quot;2022-10-25|MR|2022-10-25&quot;
        ],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: [
          &quot;2022-09-27|CT|2022-09-27&quot;,
          &quot;2022-09-29|CT|2022-09-29&quot;,
          &quot;2022-10-25|MR|2022-10-25&quot;
        ]
      },
      &quot;pathology&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;mutation&quot;: {
        &quot;chair&quot;: [
          &quot;OH2201222|2022-01-24&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;OH2201222|2022-01-24&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [
          &quot;OH2201222|2022-01-24&quot;
        ],
        &quot;nuclear&quot;: []
      }
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:35:58.368913&quot;,
    &quot;event&quot;: &quot;rag_key_facts&quot;,
    &quot;payload&quot;: {
      &quot;facts&quot;: &quot;DIAGNOSIS: primary=Ovarian cancer; histology=High-grade serous carcinoma; components=Adenocarcinoma;High-grade serous carcinoma\nPATHOLOGY: Adenocarcinoma consistent with high-grade serous carcinoma\nPLATINUM: status=Unknown; pfi_days=Unknown\nBIOMARKERS: CA125=Unknown; AFP=Unknown; TMB=Unknown; MSI=Unknown; PDL1_CPS=Unknown\nMUTATION_REPORT: id=OH2201222; date=2022-01-24; full_text=HRD é˜³æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:36:19.263669&quot;,
    &quot;event&quot;: &quot;rag_query&quot;,
    &quot;payload&quot;: {
      &quot;query&quot;: &quot;High-grade serous ovarian carcinoma with peritoneal carcinomatosis and nodal metastases (6/24 positive), HRD-positive but BRCA1/2-negative, platinum-sensitive post-adjuvant TP chemotherapy, on niraparib maintenance with severe thrombocytopenia (PLT 33-34) requiring dose modification; histology: High-grade serous carcinoma&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:36:19.263676&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;source&quot;: &quot;guideline&quot;,
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:36:19.263677&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;source&quot;: &quot;pubmed&quot;,
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:36:19.263679&quot;,
    &quot;event&quot;: &quot;rag_hits_merged&quot;,
    &quot;payload&quot;: {
      &quot;n&quot;: 10
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:36:31.653759&quot;,
    &quot;event&quot;: &quot;mdt_discussion_start&quot;,
    &quot;payload&quot;: {
      &quot;num_rounds&quot;: 2,
      &quot;num_turns&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:36:31.653814&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair&quot;,
      &quot;order&quot;: 1
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:36:38.037449&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair&quot;,
      &quot;chars&quot;: 459
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:36:38.037509&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist&quot;,
      &quot;order&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:36:44.088371&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist&quot;,
      &quot;chars&quot;: 528
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:36:44.088432&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;radiologist&quot;,
      &quot;order&quot;: 3
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:36:49.044608&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;radiologist&quot;,
      &quot;chars&quot;: 409
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:36:49.044670&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist&quot;,
      &quot;order&quot;: 4
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:36:54.017907&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist&quot;,
      &quot;chars&quot;: 410
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:36:54.017980&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;nuclear&quot;,
      &quot;order&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:36:58.606476&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;nuclear&quot;,
      &quot;chars&quot;: 378
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:37:45.504285&quot;,
    &quot;event&quot;: &quot;mdt_discussion_end&quot;,
    &quot;payload&quot;: {
      &quot;merged_chars&quot;: 1224
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:37:45.505264&quot;,
    &quot;event&quot;: &quot;trial_matching_start&quot;,
    &quot;payload&quot;: {
      &quot;trials_json_path&quot;: &quot;files/all_trials_filtered.json&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:37:49.479173&quot;,
    &quot;event&quot;: &quot;trial_matching_end&quot;,
    &quot;payload&quot;: {
      &quot;recommended&quot;: false
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:37:49.479184&quot;,
    &quot;event&quot;: &quot;final_output_start&quot;,
    &quot;payload&quot;: {}
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:37:58.524437&quot;,
    &quot;event&quot;: &quot;final_output_end&quot;,
    &quot;payload&quot;: {
      &quot;final_output_chars&quot;: 2391
    }
  }
]</pre>
  </details>

  <!-- Mermaid.js for flowchart rendering -->
  <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
  <script>
    document.addEventListener('DOMContentLoaded', function() {
      mermaid.initialize({
        startOnLoad: true,
        theme: 'default',
        flowchart: {
          useMaxWidth: true,
          htmlLabels: true,
          curve: 'basis'
        },
        securityLevel: 'loose'
      });
      // Re-render mermaid charts in .mermaid-chart containers
      document.querySelectorAll('.mermaid-chart').forEach(function(el) {
        el.classList.add('mermaid');
      });
      mermaid.init(undefined, '.mermaid-chart');
    });
  </script>
</body>
</html>
